


**AOP ID and Title:**

AOP 379: Increased susceptibility to viral entry and coronavirus production leading to thrombosis and disseminated intravascular coagulation

**Short Title:** SARS-CoV2 to thrombosis and DIC

**Graphical Representation****Authors**

Shihori Tanabe, Young-J Kim, Alicia Paini, Sally Mayasich, Maria J Amorim, Nikolaos Parissis, Penny Nymark, Marvin Martens, Dan Jacobson, Felicity Gavins, Luigi Margiotta-Casaluci, Sabina Halappanavar, Natalia Reyero, Julija Filipovska, Steve Edwards, Rebecca Ram, Adrienne Layton, and CIAO members

**Status**

**Author status**

**OECD status** **OECD project** **SAAOP status**

Under development: Not open for comment. Do not cite

## Abstract

Coronavirus disease-19 (COVID-19) is circulating all over the world. To understand and find a way of the COVID-19 treatment, the signaling pathway and therapeutic mechanism of COVID-19 should be investigated. The pathogenesis of COVID-19 includes molecular networks such as the binding of the membrane proteins, signaling pathways, and RNA replication. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a new type of coronavirus causing COVID-19, infects the cells via the binding of the membrane proteins of human cells and is internalized by the cells. The viral genome is replicated by RNA-dependent RNA polymerase (RdRp), followed by the packaging and releasing of the viral particles. These steps can be the main targets for the therapeutics of COVID-19. The AOP379 "Increased susceptibility to viral entry and coronavirus production leading to thrombosis and disseminated intravascular coagulation" consists of the molecular initiating events (MIE) as "Increased susceptibility to viral entry" (KE1738) and "Increased coronavirus production" (KE1847), key events (KEs) as "Oxidative stress response" (KE1869) and "Coagulation" (KE1845), and adverse outcome (AO) as "Thrombosis and Disseminated Intravascular Coagulation" (KE1846).

## Summary of the AOP

### Events

#### Molecular Initiating Events (MIE), Key Events (KE), Adverse Outcomes (AO)

| Sequence | Type | Event ID | Title                                                                   | Short name                              |
|----------|------|----------|-------------------------------------------------------------------------|-----------------------------------------|
| 1        | MIE  | 1738     | <a href="#">Increased susceptibility to viral entry</a>                 | Increased susceptibility to viral entry |
| 2        | MIE  | 1847     | <a href="#">Increased coronavirus production</a>                        | Increased SARS-CoV-2 production         |
| 3        | KE   | 1869     | <a href="#">Down-regulation of protective oxidative stress response</a> | Response to ROS                         |
| 4        | KE   | 1845     | <a href="#">Coagulation</a>                                             | Coagulation                             |
| 5        | AO   | 1846     | <a href="#">Thrombosis and Disseminated Intravascular Coagulation</a>   | Thrombosis and DIC                      |

### Key Event Relationships

| Upstream Event                                                          | Relationship Type | Downstream Event                                        | Evidence | Quantitative Understanding |
|-------------------------------------------------------------------------|-------------------|---------------------------------------------------------|----------|----------------------------|
| <a href="#">Increased susceptibility to viral entry</a>                 | adjacent          | Increased coronavirus production                        | High     | Moderate                   |
| <a href="#">Increased coronavirus production</a>                        | adjacent          | Down-regulation of protective oxidative stress response | Moderate | Not Specified              |
| <a href="#">Down-regulation of protective oxidative stress response</a> | adjacent          | Coagulation                                             | Moderate | Not Specified              |
| <a href="#">Coagulation</a>                                             | adjacent          | Down-regulation of protective oxidative stress response | Moderate | Not Specified              |
| <a href="#">Coagulation</a>                                             | adjacent          | Thrombosis and Disseminated Intravascular Coagulation   | High     |                            |

### Stressors

| Name                    | Evidence |
|-------------------------|----------|
| Stressor:624 SARS-CoV-2 | High     |

## Overall Assessment of the AOP

### Domain of Applicability

#### Life Stage Applicability

| Life Stage      | Evidence |
|-----------------|----------|
| All life stages | Moderate |

#### Taxonomic Applicability

| Term                                                                                                                                                                                                                                                                                               | Scientific Term | Evidence | Links                    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------|--------------------------|
| Homo sapiens                                                                                                                                                                                                                                                                                       | Homo sapiens    | High     | <a href="#">NCBI</a>     |
| Sex Applicability                                                                                                                                                                                                                                                                                  |                 |          |                          |
| Sex                                                                                                                                                                                                                                                                                                | Evidence        |          |                          |
| Unspecific                                                                                                                                                                                                                                                                                         | High            |          |                          |
| References                                                                                                                                                                                                                                                                                         |                 |          |                          |
| Blanco Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 181;(5):1036-1045.                                                                                                                      |                 |          |                          |
| Chen B, Tian EK, He B, Tian L, Han R, Wang S, et al. Overview of lethal human Coronaviruses. Signal Transduction and Targeted Therapy, 2020;5(1):89.                                                                                                                                               |                 |          |                          |
| Cui J, Li F, Shi ZL. Origin and evolution of pathogenic Coronaviruses. Nature Reviews Microbiology. 2019;17(3):181-192.                                                                                                                                                                            |                 |          |                          |
| Florindo HF, Kleiner R, Vaskovich-Koubi D, Acúrcio RC, Carreira B, Yeini,E, et al. Immune-mediated approaches against COVID-19. Nature Nanotechnology. 2020;15(8):630-45.                                                                                                                          |                 |          |                          |
| Kowalewski J, Ray A. Predicting novel drugs for SARS-CoV-2 using machine learning from a & g 10 million chemical space. Heliyon. 2020;6(8).                                                                                                                                                        |                 |          |                          |
| Pizzorno A, Padey B, Julien T, Trouillet-Assant S, Traversier A, Errazuriz-Cerda E, et al. Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia. Cell Reports Medicine. 2020;1(4).                                                                           |                 |          |                          |
| Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020.                                                                                                                               |                 |          |                          |
| Tanabe S (2020a). Cellular Internalization and RNA Regulation of RNA virus. Adv Clin Med Res. 2020;1(1):1-3. <a href="https://www.genesispub.org/cellular-internalization-and-rna-regulation-of-rna-virus">https://www.genesispub.org/cellular-internalization-and-rna-regulation-of-rna-virus</a> |                 |          |                          |
| Tanabe S (2020b). The Therapeutic Mechanism of COVID-19. J Clin Med Res. 2020;2(5):1-3. DOI: <a href="https://doi.org/10.37191/Mapsci-2582-4333-2(5)-048">https://doi.org/10.37191/Mapsci-2582-4333-2(5)-048</a>                                                                                   |                 |          |                          |
| Appendix 1                                                                                                                                                                                                                                                                                         |                 |          |                          |
| List of MIEs in this AOP                                                                                                                                                                                                                                                                           |                 |          |                          |
| <a href="#">Event: 1738: Increased susceptibility to viral entry</a>                                                                                                                                                                                                                               |                 |          |                          |
| Short Name: Increased susceptibility to viral entry                                                                                                                                                                                                                                                |                 |          |                          |
| Key Event Component                                                                                                                                                                                                                                                                                |                 |          |                          |
| Process                                                                                                                                                                                                                                                                                            |                 | Object   | Action                   |
| endocytosis involved in viral entry into host cell                                                                                                                                                                                                                                                 |                 |          | increased                |
| protease binding                                                                                                                                                                                                                                                                                   |                 |          | increased                |
| neuropilin binding                                                                                                                                                                                                                                                                                 |                 |          | increased                |
| AOPs Including This Key Event                                                                                                                                                                                                                                                                      |                 |          |                          |
| AOP ID and Name                                                                                                                                                                                                                                                                                    |                 |          | Event Type               |
| <a href="#">Aop:320 - Binding of viral S-glycoprotein to ACE2 receptor leading to acute respiratory distress associated mortality</a>                                                                                                                                                              |                 |          | KeyEvent                 |
| <a href="#">Aop:379 - Increased susceptibility to viral entry and coronavirus production leading to thrombosis and disseminated intravascular coagulation</a>                                                                                                                                      |                 |          | MolecularInitiatingEvent |

| AOP ID and Name                                                                                                                                                                                       | Event Type |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| <a href="#">Aop:394 - Sars-cov-2 infection leading to impaired olfactory function (anosmia)</a>                                                                                                       | KeyEvent   |
| <a href="#">Aop:395 - Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on pericytes leads to disseminated intravascular coagulation resulting in cerebrovascular disease (stroke)</a> | KeyEvent   |
| <a href="#">Aop:406 - SARS-CoV-2 infection leading to hyperinflammation</a>                                                                                                                           | KeyEvent   |
| <a href="#">Aop:407 - SARS-CoV-2 infection leading to pyroptosis</a>                                                                                                                                  | KeyEvent   |
| <a href="#">Aop:426 - SARS-CoV-2 spike protein binding to ACE2 receptors expressed on pericytes leads to endothelial cell dysfunction, microvascular injury and myocardial infarction.</a>            | KeyEvent   |
| <a href="#">Aop:422 - Binding of SARS-CoV-2 to ACE2 in enterocytes leads to increased intestinal permeability resulting in GI disorders</a>                                                           | KeyEvent   |
| <a href="#">Aop:430 - Sars-CoV-2 Interferon-I antiviral response antagonism and increased viral production leading to viral infection proliferation</a>                                               | KeyEvent   |

## Stressors

### Name

Sars-CoV-2

## Biological Context

### Level of Biological Organization

Molecular

### Cell term

#### Cell term

cell

### Organ term

#### Organ term

organ

## Domain of Applicability

### Taxonomic Applicability

| Term                  | Scientific Term        | Evidence      | Links                |
|-----------------------|------------------------|---------------|----------------------|
| Homo sapiens          | Homo sapiens           | High          | <a href="#">NCBI</a> |
| Manis javanica        | Manis javanica         | Low           | <a href="#">NCBI</a> |
| Canis familiaris      | Canis lupus familiaris | Moderate      | <a href="#">NCBI</a> |
| Macaca fascicularis   | Macaca fascicularis    | Not Specified | <a href="#">NCBI</a> |
| Mesocricetus auratus  | Mesocricetus auratus   | Not Specified | <a href="#">NCBI</a> |
| Mustela putorius furo | Mustela putorius furo  | Not Specified | <a href="#">NCBI</a> |
| Felis catus           | Felis catus            | Moderate      | <a href="#">NCBI</a> |
| Mustela lutreola      | Mustela lutreola       | High          | <a href="#">NCBI</a> |
| Neovison vison        | Neovison vison         | High          | <a href="#">NCBI</a> |
| Panthera tigris       | Panthera tigris        | Moderate      | <a href="#">NCBI</a> |

### Life Stage Applicability

Life Stage Evidence

## All life stages High Life Stage Evidence Sex Applicability

### Sex Evidence

Unspecific High

Male High

TMPRSS2 vertebrates (Lam et al., 2020)

NRP1 in human & rodents (but also present in monkey and other vertebrates (Lu and Meng, 2015)

The ability for SARS-CoV-2 to use multiple host pathways for viral entry, means that it is critical to map which viral entry pathway is prevalent in specific cell types. This is key for understanding coronavirus biology, but also use informed decisions to select cells for cell-based genetic and small-molecule screens and to interpret data. In fact, a combination of protease inhibitors that block both TMPRSS2 and cathepsin L is the most efficient combination to block coronavirus infection (Yamamoto et al., 2020, Shang et al., 2020, Shirato et al., 2018). In accordance, SARS-CoV-2 entry processes are highly dependent on endocytosis and endocytic maturation in cells that do not express TMPRSS2, such as VeroE6 or 293T cells (Murgolo et al., 2021, Kang et al., 2020, Mirabelli et al., 2020, Riva et al., 2020). However, even in these cells, heterologous expression of TMPRSS2 abrogates the pharmacological blockade of cathepsin inhibitors (Kawase et al., 2012, Hoffmann et al., 2020a). Treatment of SARS-CoV-2 with trypsin enables viral cell surface entry, even when TMPRSS2 is absent. Moreover, TMPRSS2 is more efficient to promote viral entry than cathepsins (Lamers et al., 2020), as when both factors are present, cathepsin inhibitors are less effective than TMPRSS2 inhibitors (Hoffmann et al., 2020b). Therefore it is critical to map which cells contain the different types of proteases.

In summary, TMPRSS2 appears to be expressed in a wide range of healthy adult organs, but in restricted cell types, including:

- AT2 and clara cells of lungs
- sinusoidal endothelium, and hepatocyte of the liver,
- endocrine cells of the prostate,
- goblet cells , and enterocytes of the small intestine,
- intercalated cells, and the proximal tubular of the kidney.
- Ciliated, secretory and suprabasal of nasal
- spermatogonial stem cells of testes
- cyto trophoblast and peri vascular cells of placenta
- The nasal epithelium expresses various combinations of factors that, in principle, could facilitate SARS-CoV-2 infection, but it also expresses robust basal levels of RFs, which may act as a strong protective barrier in this tissue.

There is a shift in TMPRSS2 regulation during nasal epithelium differentiation in young individuals that is not occurring in old individuals (Lin et al., 1999, Lucas et al., 2008, Singh et al., 2020).

Only a small minority of human respiratory and intestinal cells have genes that express both ACE2 and TMPRSS2. Amongst the ones that do, three main cell types were identified: A) lung cells called type II pneumocytes (which help maintain air sacs, known as alveoli); B) intestinal cells called enterocytes, which help the body absorb nutrients; and C) goblet cells in the nasal passage, which secrete mucus (Ziegler et al., 2020).

The clinical manifestations of COVID-19 include not only complications from acute myocardial injury, elevated liver enzymes, and acute kidney injury in patients presenting to hospitals, but also gastrointestinal symptoms in community patients experiencing milder forms of the disease (Madjid et al., 2020, Pan et al., 2020).

### NRP-1:

All life stages

The expression of isoforms 1 (NRP1) and 2 (NRP2) does not seem to overlap. Isoform 1 is expressed by the blood vessels of different tissues. In the developing embryo it is found predominantly in the nervous system. In adult tissues, it is highly expressed in heart and placenta; moderately in lung, liver, skeletal muscle, kidney and pancreas; and low in adult brain. Isoform 2 is found in liver hepatocytes, kidney distal and proximal tubules. Expressed in colon and 234 other tissues with Low tissue specificity (UniProtKB).

The expression of NRP1 protein in gastric cancer was not related to gender or age (Cao et al., 2020).

### Sex Applicability:

#### TMPRSS2:

Androgen receptors (ARs) play a key role in the transcription of TMPRSS2 (Fig. 1). This may explain the predominance of males to COVID-19 infection, fatality, and severity because males tend to have a higher expression and activation of ARs than females, which is due to the presence of dihydrotestosterone (DHT).

Regulation of COVID-19 severity and fatality by sex hormones. Females have aromatase, the enzyme that converts androgen substrates into estrogen. On the other hand, males have steroid 5 $\alpha$  reductase, the enzyme that is responsible for the conversion of testosterone into dihydrotestosterone (DHT). In case of males, DHT activates androgen receptor (AR) that binds to the androgen response element (ARE)

present in the promoter of TMPRSS2 gene, leading to its transcription. This ultimately results into enhanced processing of viral spike protein for greater entry and spread of SARS-CoV-2 into host cells. On the other hand, in females, estrogen activates estrogen receptor (ER), which binds to the estrogen response element (ERE) present in the promoter of eNOS gene to drive its transcription and catalyze the formation of nitric oxide (NO) from L-arginine. This NO is involved in vasodilation as well as inhibition of viral replication.

#### NRP-1:

For more information difference of NRP1 expression between male and female see <https://www.proteinatlas.org/ENSG00000099250-NRP1/tissue>.

The expression of NRP1 protein in gastric cancer was not related to gender, age. The expression of NRP1 protein in gastric cancer is closely correlated to clinical stage, tumor size, TNM stage, differentiation, and lymph node metastasis (Cao et al., 2020).

SARS-CoV-2 Spike protein co-opts VEGF-A/Neuropilin-1 receptor signalling to induce analgesia had same results on both male and female rodents (Moutal et al., 2020).

### Key Event Description

Coronavirus is recognized by the binding of S protein on the viral surface and angiotensin-converting enzyme 2 (ACE2) receptor on the cellular membrane, followed by viral entry via processing of S protein by transmembrane serine protease 2 (TMPRSS2) (Hoffmann et al., 2020b). ACE2 is expressed on epithelial cells of the lung and intestine, and also can be found in the heart, kidney, adipose, and male and female reproductive tissues (Lukassen et al., 2020, Lamers et al., 2020, Chen et al., 2020, Jing et al., 2020, Subramanian et al., 2020).

SARS-CoV-2 is an enveloped virus characterized by displaying spike proteins at the viral surface (Juraszek et al., 2021). Spike is critical for viral entry (Hoffmann et al., 2020b) and is the primary target of vaccines and therapeutic strategies, as this protein is the immunodominant target for antibodies (Yuan et al., 2020, Ju et al., 2020, Robbiani et al., 2020, Premkumar et al., 2020, Liu et al., 2020). Spike is composed of S1 and S2 subdomains. S1 contains the N-terminal (NTD) and receptor-binding (RBD) domains, and the S2 contains the fusion peptide (FP), heptad repeat 1 (HR1) and HR2, the transmembrane (TM) and cytoplasmic domains (CD) (Lan et al., 2020). S1 leads to the recognition of the angiotensin-converting enzyme 2 (ACE2) receptor and S2 is involved in membrane fusion (Hoffmann et al., 2020b, Letko et al., 2020, Shang et al., 2020).

Upon binding to ACE2, the spike protein needs to be activated (or primed) through proteolytic cleavage (by a host protease) to allow membrane fusion. Fusion is a key step in viral entry as it is the way to release SARS-CoV-2 genetic material inside the cell. Cleavage happens between its spike's S1 and S2 domains, liberating S2 that inserts its N-terminal domain into a host cell membrane and mediates membrane fusion (Millet and Whittaker, 2018). Many proteases were identified to activate coronaviruses including furin, cathepsin L, trypsin-like serine proteases TMPRSS2, TMPRSS4, TMPRSS11, and human airway trypsin-like protease (HATs). These may operate at four different stages of the virus infection cycle: (a) pro-protein convertases (e.g., furin) during virus packaging in virus-producing cells, (b) extracellular proteases (e.g., elastase) after virus release into extracellular space, (c) cell surface proteases [e.g., type II transmembrane serine protease (TMPRSS2)] after virus attachment to virus-targeting cells, and (d) lysosomal proteases (e.g., cathepsin L) after virus endocytosis in virus-targeting cells (Li, 2016). SARS-CoV-2 lipidic envelope may fuse with two distinct membrane types, depending on the host protease(s) responsible for cleaving the spike protein: (i) cell surface following activation by serine proteases such as TMPRSS2 and furin (Hoffmann et al., 2020b); or (ii) endocytic pathway within the endosomal-lysosomal compartments including processing by lysosomal cathepsin L (Yang and Shen, 2020). These flexibility for host cell factors mediating viral entry, highlights that the availability of factors existing in a cell type dictates the mechanism of viral entry (Kawase et al., 2012). When TMPRSS2 (or other serine proteases such as TMPRSS4 (Zang et al., 2020) or human airway trypsin-like protease [HAT] (Bestle et al., 2020a)) is expressed, fusion of the virus with the cell surface membrane is preferred (Shirato et al., 2018), while in their absence, the virus can penetrate the cell by endocytosis (Kawase et al., 2012). A third factor has also been shown to facilitate SARS-CoV-2 entry in cells that have ACE2 and even promote, although to very low levels, SARS-CoV-2 entry in cells that lack ACE2 and TMPRSS2 which is the neuropilin-1 (NRP-1) (Cantuti-Castelvetri et al., 2020). This key event deals with SARS-CoV-2 entry in host cells and is divided in three categories: TMPRSS2, cathepsin L and NRP-1.

#### TMPRSS2 Spike cleavage:

TMPRSS2 (transmembrane serine protease 2, (<https://www.ncbi.nlm.nih.gov/gene/7113>) is a cell-surface protease (Hartenian et al., 2020) that facilitates entry of viruses into host cells by proteolytically cleaving and activating viral envelope glycoproteins. Viruses found to use this protein for cell entry include Influenza virus and the human coronaviruses HCoV-229E, MERS-CoV, SARS-CoV and SARS-CoV-2 (COVID-19 virus).

TMPRSS2 is a membrane bound serine protease also known as epitheliasin. TMPRSS2 belongs to the S1A class of serine proteases alongside proteins such as factor Xa and trypsin. Whilst there is evidence that TMPRSS2 autocleaves to generate a secreted protease, its physiological function has not been clearly identified. However, it is known to play a crucial role in facilitating entry of coronavirus particles into cells by cleaving the spike protein (Huggins, 2020).

After ACE2 receptor binding, SARS-CoV-2 S proteins can be subsequently cleaved and activated by host cell-surface protease at the S1/S2 and S2' sites, generating the subunits S1 and S2 that remain non-covalently linked. Cleavage leads to activation of the S2 domain that drives fusion of the viral and host membranes (Hartenian et al., 2020, Walls et al., 2016). For other coronaviruses, processing of spike was proposed to be sequential with S1/S2 cleavage preceding that of S2. Cleavage at S1/S2 may be crucial for inducing conformational changes required for receptor binding or exposure of the S2 site to host proteases.

The S1/S2 site of SARS-CoV-2 S protein contains an insertion of four amino acids providing a minimal furin cleavage site (RRAR685↓) (that is absent in SARS-CoV). Interestingly, the furin cleavage site has been implicated in increased viral pathogenesis (Bestle et al., 2020b, Huggins, 2020). Processing of the spike protein by furin at the S1/S2 cleavage site is thought to occur following viral replication in the endoplasmic reticulum Golgi intermediate compartment (ERGIC) (Hasan et al., 2020). The spike S2' cleavage site of SARS-CoV-2 possesses a paired dibasic motif with a single KR segment (KR815↓) (as SARS-CoV) that is recognized by trypsin-like serine proteases such as TMPRSS2. **The**

**current data support a model for SARS-CoV-2 entry in which furin-mediated cleavage at the S1/S2 site pre-primes spike during biogenesis, facilitating the activation for membrane fusion by a second cleavage event at S2' by TMPRSS2 following ACE2 binding** (Bestle et al., 2020b, Johnson et al., 2020).

| Virus      | S1/S2 site           | S2' site               |
|------------|----------------------|------------------------|
| SARS-CoV-2 | TNSP <b>RRAR</b> SVa | PSKPS <b>KR</b> SFIEDL |
| SARS-CoV   | S---LLR <b>ST</b> S  | PLKPT <b>KR</b> SFIEDL |

Camostat mesylate, an inhibitor of TMPRSS2, blocks SARS-CoV-2 infection of lung cells like Calu-3 cells but not Huh7.5 and Vero E6 cells. Cell entry was assessed using a viral isolate and viral pseudotypes (artificial viruses) expressing the COVID-19 spike (S) protein. The ability of the viral pseudotypes (expressing S protein from SARS-CoV and SARS-CoV-2) to enter human and animal cell lines was demonstrated, showing that SARS-CoV-2 can enter similar cell lines as SARS-CoV. Amino acid analysis and cell culture experiments showed that, like SARS-CoV, SARS-CoV-2 spike protein binds to human and bat angiotensin-converting enzyme 2 (ACE2) and uses a cellular protease TMPRSS2 for priming. Priming activates the spike protein to facilitate viral fusion and entry into cells. Cell culture experiments were performed using immortalized cell lines and primary human lung cells (Hoffmann et al., 2020b, Rahman et al., 2020).

### Spike binding to neuropilin-1:

Neuropilin-1 (NRP1) is a transmembrane glycoprotein that serves as a cell surface receptor for semaphorins and various ligands involved in angiogenesis in vertebrates. NRP1 is expressed in neurons, blood vessels (endothelial cells), immune cells and many other cell types in the mammalian body (maternal fetal interface) and binds a range of structurally and functionally diverse extracellular ligands to modulate organ development and function (Raimondi et al., 2016). NRP1 is well described as a co-receptor for members of the class 3 semaphorins (SEMA3) or vascular endothelial growth factors (VEGFs) (Gelfand et al., 2014). Structurally, NRP1 comprises seven sub-domains, of which the first five are extracellular; two CUB domains (a1 and a2), two coagulation factor V/VIII domains (FV/VIII; b1 and b2) and a meprin, A5  $\mu$ -phosphatase domain (MAM; c). NRP1 contains only a short cytosolic tail with a PDZ-binding domain lacking internal signaling activity. The different ligand families bind to different sites of NRP1; SEMA3A binding requires the first three sub-domains of NRP1 (a1, a2, and b1), whereas binding of VEGF-A requires the b1 and b2 domains (Muhl et al., 2017). Additional studies conducted by means of in silico computational technology to identify and validate inhibitors of the interaction between NRP1 and SARS-CoV-2 Spike protein are reported in (Perez-Miller et al., 2020). Represents a schematic picture of VEGF-A triggered phosphorylation of VEGF-R2. Screening of NRP-1/VEGF-A165 inhibitors by in-cell Western (Perez-Miller et al., 2020).v NRP1 acts as a co-receptor for SARS-CoV-2.

NRP1 is a receptor for furin-cleaved SARS-CoV-2 spike peptide (Cantuti-Castelvetri et al., 2020, Daly et al., 2020, Johnson et al., 2020). Blockade of NRP1 reduces infectivity and entry, and alteration of the furin site leads to loss of NRP1 dependence, reduced replication in Calu3, augmented replication in Vero E6, and attenuated disease in a hamster pathogenesis disease model (Johnson et al., 2020). In fact, a small sequence of amino acids was found that appeared to mimic a protein sequence found in human proteins that interact with NRP1. The spike protein of SARS-CoV-2 binding with NRP1 aids viral infection of human cells. This was confirmed by applying a range of structural and biochemical approaches to establish that the spike protein of SARS-CoV-2 does indeed bind to NRP1. The host protease furin cleaves the full-length precursor S glycoprotein into two associated polypeptides: S1 and S2. Cleavage of S generates a polybasic RRAR C-terminal sequence on S1, which conforms to a C-end rule (CendR) motif that binds to cell surface neuropilin-1 (NRP1) and neuropilin-2 (NRP2) receptors. It was reported that the S1 CendR motif directly bound NRP1 by X-ray crystallography and biochemical approaches. Blocking this interaction using RNAi or selective inhibitors reduced SARS-CoV-2 entry and infectivity in cell culture (Daly et al., 2020).

NRP1, known to bind furin-cleaved substrates, significantly potentiates SARS-CoV-2 infectivity, which was revealed by a monoclonal blocking antibody against NRP1. It was found that a SARS-CoV-2 mutant with an altered furin cleavage site did not depend on NRP1 for infectivity. Pathological analysis of olfactory epithelium obtained from human COVID-19 autopsies revealed that SARS-CoV-2 infected NRP1-positive cells faced the nasal cavity (Cantuti-Castelvetri et al., 2020). Furthermore, it has been found that NRP1 is a new potential SARS-CoV-2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID-19. Preclinical studies have suggested that NRP1, a transmembrane receptor that lacks a cytosolic protein kinase domain and exhibits high expression in the respiratory and olfactory epithelium, may also be implicated in COVID-19 by enhancing the entry of SARS-CoV-2 into the brain through the olfactory epithelium. NRP1 is also expressed in the CNS, including olfactory-related regions such as the olfactory tubercles and paraolfactory gyri. Supporting the potential role of NRP1 as an additional SARS-CoV-2 infection mediator implicated in the neurologic manifestations of COVID-19. Accordingly, the neurotropism of SARS-CoV-2 via NRP1-expressing cells in the CNS merits further investigation (Davies et al., 2020).

Up-regulation of NRP1 protein in diabetic kidney cells hints at its importance in a population at risk of severe COVID-19. Involvement of NRP-1 in immune function is compelling, given the role of an exaggerated immune response in disease severity and deaths due to COVID-19. NRP-1 has been suggested to be an immune checkpoint of T cell memory. It is unknown whether involvement and up-regulation of NRP-1 in COVID-19 may translate into disease outcome and long-term consequences, including possible immune dysfunction (Mayi et al., 2021).

The main feature of NRP1 co-receptor is to form complexes with multiple other receptors. Hence, there is a competition between receptors to complex with NRP-1, which may determine their abilities both quantitatively and qualitatively to transduce signals. It is tempting to hypothesize that the occupancy of NRP-1 with one receptor may thus decrease its availability for virus entry. Recent proteomics work has shown that NRP-1 can form a complex with the  $\alpha 7$  nicotinic receptor in mice. Both receptors are expressed in the human nasal and pulmonary epithelium (Mayi et al., 2021).

NRP1, is highly expressed in the respiratory and olfactory epithelium; it is also expressed in the CNS, including olfactory related regions such as the olfactory tubercles and paraolfactory gyri (Davies et al., 2020).

More information on tissue distribution and protein expression of NRP1 can be found in <https://www.proteinatlas.org/ENSG00000099250-NRP1>

### Spike entry via lysosomal cathepsins and endocytosis:

Evidence shows the role of TMPRSS2 and other serine proteases in activating the coronavirus spike protein for plasma membrane fusion. However, studies using various cell culture systems showed that SARS-CoV2 could enter cells via an alternative endosomal-lysosomal pathway. Evidence came from studies demonstrating that lysosomotropic agents reduced SARS-CoV replication in cells lacking TMPRSS2 and other studies, using highly potent and specific small-molecule cathepsin inhibitors, to understand the role of cathepsins in processing and activating the spike for membrane fusion, mainly of cathepsin L (one of the 11 cathepsins) (Rossi et al., 2004, Simmons et al., 2005). SARS-CoV-2 and other coronaviruses can establish infection through endosomal entry in commonly used in vitro cell culture systems. Of relevance, inhibitors of the endosomal pathway, as the cathepsin inhibitor Z-FA-FMK and PIKfyve inhibitor apilimod, blocked viral entry in Huh7.5 and Vero E6 cells but not Calu-3 cells.

### How it is Measured or Detected

SARS-CoV2 entry can be determined by many different ways:

- 1) quantitative RT-PCR specific to the subgenomic mRNA of the N transcript, in cells manipulated with host factors that express or not TMPRSS2, cathepsinL, neuropilin-1, hACE2 [Glowacka I, et al. (2011)], or exogenous addition of HAT or furin.
- 2) using spike-pseudotyped viral particles expressing GFP/luciferase/bgalactosidase and comparing with vesicular stomatitis virus G pseudotyped particles expressing the same reporter analysed in manipulated cultured with cell lines, followed by determining fluorescence, bioluminescence, luciferase activity in cell lysates [Hoffmann M, et al. (2020)].

#### TMPPRSS2:

TMPPRSS2 gene expression can be measured by RNAseq and microarray (Baughn et al., 2020).

Expression levels of TMPPRSS2 can be measured by RNA in situ hybridization (RNA-ISH) (Qiao et al., 2020)

#### NRP-1:

Several methods have been identified in the literature for measuring and detecting NRP1 receptor binding. Briefly described:

1. X-ray crystallography and biochemical approaches help to show that the S1 CendR motif directly bound NRP1 (1). Binding of the S1 fragment to NRP1 was assessed and ability of SARS-CoV-2 to use NRP1 to infect cells was measured in angiotensin-converting enzyme-2 (ACE-2)-expressing cell lines by knocking out NRP1 expression, blocking NRP1 with 3 different anti-NRP1 monoclonal antibodies, or using NRP1 small molecule antagonists (Centers for Disease Control and Prevention, 2020, Daly et al., 2020).

Key findings (Centers for Disease Control and Prevention, 2020, Daly et al., 2020):

- The S1 fragment of the cleaved SARS-CoV-2 spike protein binds to the cell surface receptor neuropilin-1 (NRP1).
- SARS-CoV-2 utilizes NRP1 for cell entry as evidenced by decreased infectivity of cells in the presence of: NRP1 deletion ( $p < 0.01$ ). Three different anti-NRP1 monoclonal antibodies ( $p < 0.001$ ). Selective NRP1 antagonist, EG00229 ( $p < 0.01$ ).
- 2. Cell lines were modified to express ACE2 and TMPPRSS2, the two known SARS-CoV-2 host factors, and NRP1 to assess the contribution of NRP1 to infection. Autopsy specimens from multiple airway sites were stained with antibodies against SARS-CoV-2 proteins, ACE2, and NRP1, to visualize co-localization of proteins (6, 15).

Key findings (Cantuti-Castelvetri et al., 2020, Centers for Disease Control and Prevention, 2020):

- Infectivity of cells expressing angiotensin converting enzyme-2 (ACE2, receptor for SARS-CoV-2), transmembrane protease serine-2 (TSS2, primes the Spike [S] protein), and neuropilin-1 (NRP1) with pseudovirus expressing the SARS-CoV-2 S1 protein was approximately 3-fold higher than in cells expressing either ACE2 or TSS2 alone ( $p < 0.05$ ).
- Analysis of autopsy tissue from COVID-19 patients showed co-localization of the SARS-CoV-2 spike (S) protein and NRP1 in olfactory and respiratory epithelium.

Virtual screen of nearly 0.5 million compounds against the NRP-1 CendR site, resulting in nearly 1,000 hits. A pharmacophore model was derived from the identified ligands, considering both steric and electronic requirements. Preparation of receptor protein and grid for virtual screening, docking of known NRP-1 targeting compounds, ELISA based NRP1-VEGF-A165 protein binding assay; more details on methodology in the referenced paper (Perez-Miller et al., 2020)

### References

- BAUGHN, L. B., SHARMA, N., ELHAIK, E., SEKULIC, A., BRYCE, A. H. & FONSECA, R. 2020. Targeting TMPRSS2 in SARS-CoV-2 Infection. *Mayo Clin Proc*, 95, 1989-1999.
- BESTLE, D., HEINDL, M. R., LIMBURG, H., VAN LAM VAN, T., PILGRAM, O., MOULTON, H., STEIN, D. A., HARDES, K., EICKMANN, M., DOLNIK, O., ROHDE, C., KLENK, H.-D., GARTEN, W., STEINMETZER, T. & BÖTTCHER-FRIEBERTSHAUSER, E. 2020a. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. *Life Science Alliance*, 3.
- BESTLE, D., HEINDL, M. R., LIMBURG, H., VAN LAM VAN, T., PILGRAM, O., MOULTON, H., STEIN, D. A., HARDES, K., EICKMANN, M., DOLNIK, O., ROHDE, C., KLENK, H. D., GARTEN, W., STEINMETZER, T. & BOTTCHER-FRIEBERTSHAUSER, E. 2020b. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. *Life Sci Alliance*, 3.

- CANTUTI-CASTELVETRI, L., OJHA, R., PEDRO, L. D., DJANNATIAN, M., FRANZ, J., KUIVANEN, S., VAN DER MEER, F., KALLIO, K., KAYA, T., ANASTASINA, M., SMURA, T., LEVANOV, L., SZIROVICZA, L., TOBI, A., KALLIO-KOKKO, H., OSTERLUND, P., JOENSUU, M., MEUNIER, F. A., BUTCHER, S. J., WINKLER, M. S., MOLLENHAUER, B., HELENIUS, A., GOKCE, O., TEESALU, T., HEPOJOKI, J., VAPALAHTI, O., STADELMANN, C., BALISTRERI, G. & SIMONS, M. 2020. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. *Science*, 370, 856-860.
- CAO, H., LI, Y., HUANG, L., BAI, B. & XU, Z. 2020. Clinicopathological Significance of Neuropilin 1 Expression in Gastric Cancer: A Meta-Analysis. *Dis Markers*, 2020, 4763492.
- CENTERS FOR DISEASE CONTROL AND PREVENTION, U. S. D. O. H. A. H. S. 2020. Covid-19 Science Update 2020.
- CHEN, L., LI, X., CHEN, M., FENG, Y. & XIONG, C. 2020. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. *Cardiovasc Res*, 116, 1097-1100.
- DALY, J. L., SIMONETTI, B., KLEIN, K., CHEN, K. E., WILLIAMSON, M. K., ANTON-PLAGARO, C., SHOEMARK, D. K., SIMON-GRACIA, L., BAUER, M., HOLLANDI, R., GREBER, U. F., HORVATH, P., SESSIONS, R. B., HELENIUS, A., HISCOX, J. A., TEESALU, T., MATTHEWS, D. A., DAVIDSON, A. D., COLLINS, B. M., CULLEN, P. J. & YAMAUCHI, Y. 2020. Neuropilin-1 is a host factor for SARS-CoV-2 infection. *Science*, 370, 861-865.
- DAVIES, J., RANDEVA, H. S., CHATHA, K., HALL, M., SPANDIDOS, D. A., KARTERIS, E. & KYROU, I. 2020. Neuropilin1 as a new potential SARSCoV2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID19. *Mol Med Rep*, 22, 4221-4226.
- GELFAND, M. V., HAGAN, N., TATA, A., OH, W. J., LACOSTE, B., KANG, K. T., KOPYCINSKA, J., BISCHOFF, J., WANG, J. H. & GU, C. 2014. Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding. *Elife*, 3, e03720.
- HARTENIAN, E., NANDAKUMAR, D., LARI, A., LY, M., TUCKER, J. M. & GLAUNSINGER, B. A. 2020. The molecular virology of coronaviruses. *J Biol Chem*, 295, 12910-12934.
- HASAN, A., PARAY, B. A., HUSSAIN, A., QADIR, F. A., ATTAR, F., AZIZ, F. M., SHARIFI, M., DERAKHSHANKHAH, H., RASTI, B., MEHRABI, M., SHAHPASAND, K., SABOURY, A. A. & FALAHATI, M. 2020. A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin. *J Biomol Struct Dyn*, 1-9.
- HOFFMANN, M., KLEINE-WEBER, H. & POHLMANN, S. 2020a. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol Cell*, 78, 779-784 e5.
- HOFFMANN, M., KLEINE-WEBER, H., SCHROEDER, S., KRUGER, N., HERRLER, T., ERICHSEN, S., SCHIERGENS, T. S., HERRLER, G., WU, N. H., NITSCHKE, A., MULLER, M. A., DROSTEN, C. & POHLMANN, S. 2020b. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*, 181, 271-280 e8.
- HUGGINS, D. J. 2020. Structural analysis of experimental drugs binding to the SARS-CoV-2 target TMPRSS2. *J Mol Graph Model*, 100, 107710.
- JING, Y., RUN-QIAN, L., HAO-RAN, W., HAO-RAN, C., YA-BIN, L., YANG, G. & FEI, C. 2020. Potential influence of COVID-19/ACE2 on the female reproductive system. *Mol Hum Reprod*, 26, 367-373.
- JOHNSON, B. A., XIE, X., KALVERAM, B., LOKUGAMAGE, K. G., MURUATO, A., ZOU, J., ZHANG, X., JUELICH, T., SMITH, J. K., ZHANG, L., BOPP, N., SCHINDEWOLF, C., VU, M., VANDERHEIDEN, A., SWETNAM, D., PLANTE, J. A., AGUILAR, P., PLANTE, K. S., LEE, B., WEAVER, S. C., SUTHAR, M. S., ROUTH, A. L., REN, P., KU, Z., AN, Z., DEBBINK, K., SHI, P. Y., FREIBERG, A. N. & MENACHERY, V. D. 2020. Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis. *bioRxiv*.
- JU, B., ZHANG, Q., GE, J., WANG, R., SUN, J., GE, X., YU, J., SHAN, S., ZHOU, B., SONG, S., TANG, X., YU, J., LAN, J., YUAN, J., WANG, H., ZHAO, J., ZHANG, S., WANG, Y., SHI, X., LIU, L., ZHAO, J., WANG, X., ZHANG, Z. & ZHANG, L. 2020. Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*, 584, 115-119.
- JURASZEK, J., RUTTEN, L., BLOKLAND, S., BOUCHIER, P., VOORZAAT, R., RITSCHKE, T., BAKKERS, M. J. G., RENAULT, L. L. R. & LANGEDIJK, J. P. M. 2021. Stabilizing the closed SARS-CoV-2 spike trimer. *Nat Commun*, 12, 244.
- KANG, Y.-L., CHOU, Y.-Y., ROTHLAUF, P. W., LIU, Z., SOH, T. K., CURETON, D., CASE, J. B., CHEN, R. E., DIAMOND, M. S., WHELAN, S. P. J. & KIRCHHAUSEN, T. 2020. Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. *bioRxiv*, 2020.04.21.053058.
- KAWASE, M., SHIRATO, K., VAN DER HOEK, L., TAGUCHI, F. & MATSUYAMA, S. 2012. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. *J Virol*, 86, 6537-45.
- LAM, S. D., BORDIN, N., WAMAN, V. P., SCHOLLES, H. M., ASHFORD, P., SEN, N., VAN DORP, L., RAUER, C., DAWSON, N. L., PANG, C. S. M., ABBASIAN, M., SILLITOE, I., EDWARDS, S. J. L., FRATERNALI, F., LEES, J. G., SANTINI, J. M. & ORENGO, C. A. 2020. SARS-CoV-2 spike protein predicted to form complexes with host receptor protein orthologues from a broad range of mammals. *Sci Rep*, 10, 16471.
- LAMERS, M. M., BEUMER, J., VAN DER VAART, J., KNOOPS, K., PUSCHHOF, J., BREUGEM, T. I., RAVELLI, R. B. G., PAUL VAN SCHAYCK, J., MYKYTYN, A. Z., DUIMEL, H. Q., VAN DONSELAAR, E., RIESEBOSCH, S., KUIJPERS, H. J. H., SCHIPPER, D., VAN DE WETERING, W. J., DE GRAAF, M., KOOPMANS, M., CUPPEN, E., PETERS, P. J., HAAGMANS, B. L. & CLEVERS, H. 2020. SARS-CoV-2 productively infects human gut enterocytes. *Science*, 369, 50-54.

- LAN, J., GE, J., YU, J., SHAN, S., ZHOU, H., FAN, S., ZHANG, Q., SHI, X., WANG, Q., ZHANG, L. & WANG, X. 2020. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature*, 581, 215-220.
- LETKO, M., MARZI, A. & MUNSTER, V. 2020. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol*, 5, 562-569.
- LI, F. 2016. Structure, Function, and Evolution of Coronavirus Spike Proteins. *Annu Rev Virol*, 3, 237-261.
- LIN, B., FERGUSON, C., WHITE, J. T., WANG, S., VESSELLA, R., TRUE, L. D., HOOD, L. & NELSON, P. S. 1999. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. *Cancer Res*, 59, 4180-4.
- LIU, L., WANG, P., NAIR, M. S., YU, J., RAPP, M., WANG, Q., LUO, Y., CHAN, J. F., SAHI, V., FIGUEROA, A., GUO, X. V., CERUTTI, G., BIMELA, J., GORMAN, J., ZHOU, T., CHEN, Z., YUEN, K. Y., KWONG, P. D., SODROSKI, J. G., YIN, M. T., SHENG, Z., HUANG, Y., SHAPIRO, L. & HO, D. D. 2020. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature*, 584, 450-456.
- LU, Y. & MENG, Y. G. 2015. Quantitation of Circulating Neuropilin-1 in Human, Monkey, Mouse, and Rat Sera by ELISA. *Methods Mol Biol*, 1332, 39-48.
- LUCAS, J. M., TRUE, L., HAWLEY, S., MATSUMURA, M., MORRISSEY, C., VESSELLA, R. & NELSON, P. S. 2008. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. *J Pathol*, 215, 118-25.
- LUKASSEN, S., CHUA, R. L., TREFZER, T., KAHN, N. C., SCHNEIDER, M. A., MULEY, T., WINTER, H., MEISTER, M., VEITH, C., BOOTS, A. W., HENNIG, B. P., KREUTER, M., CONRAD, C. & EILS, R. 2020. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. *EMBO J*, 39, e105114.
- MADJID, M., SAFAVI-NAEINI, P., SOLOMON, S. D. & VARDENY, O. 2020. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. *JAMA Cardiol*, 5, 831-840.
- MAYI, B. S., LEIBOWITZ, J. A., WOODS, A. T., AMMON, K. A., LIU, A. E. & RAJA, A. 2021. The role of Neuropilin-1 in COVID-19. *PLoS Pathog*, 17, e1009153.
- MILLET, J. K. & WHITTAKER, G. R. 2018. Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells. *Virology*, 517, 3-8.
- MIRABELLI, C., WOTRING, J. W., ZHANG, C. J., MCCARTY, S. M., FURSMIDT, R., FRUM, T., KADAMBI, N. S., AMIN, A. T., O'MEARA, T. R., PRETTO, C. D., SPENCE, J. R., HUANG, J., ALYSANDRATOS, K. D., KOTTON, D. N., HANDELMAN, S. K., WOBUS, C. E., WEATHERWAX, K. J., MASHOUR, G. A., O'MEARA, M. J. & SEXTON, J. Z. 2020. Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19. *bioRxiv*, 2020.05.27.117184.
- MOUTAL, A., MARTIN, L. F., BOINON, L., GOMEZ, K., RAN, D., ZHOU, Y., STRATTON, H. J., CAI, S., LUO, S., GONZALEZ, K. B., PEREZ-MILLER, S., PATWARDHAN, A., IBRAHIM, M. M. & KHANNA, R. 2020. SARS-CoV-2 Spike protein co-opts VEGF-A/Neuropilin-1 receptor signaling to induce analgesia. *bioRxiv*.
- MUHL, L., FOLESTAD, E. B., GLADH, H., WANG, Y., MOESSINGER, C., JAKOBSSON, L. & ERIKSSON, U. 2017. Neuropilin 1 binds PDGF-D and is a co-receptor in PDGF-D-PDGFRbeta signaling. *J Cell Sci*, 130, 1365-1378.
- MUKHERJEE, S. & PAHAN, K. 2021. Is COVID-19 Gender-sensitive? *J Neuroimmune Pharmacol*, 16, 38-47.
- MURGOLO, N., THERIEN, A. G., HOWELL, B., KLEIN, D., KOEPLINGER, K., LIEBERMAN, L. A., ADAM, G. C., FLYNN, J., MCKENNA, P., SWAMINATHAN, G., HAZUDA, D. J. & OLSEN, D. B. 2021. SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development. *PLoS Pathog*, 17, e1009225.
- PAN, X. W., XU, D., ZHANG, H., ZHOU, W., WANG, L. H. & CUI, X. G. 2020. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. *Intensive Care Med*, 46, 1114-1116.
- PEREZ-MILLER, S., PATEK, M., MOUTAL, A., CABEL, C. R., THORNE, C. A., CAMPOS, S. K. & KHANNA, R. 2020. In silico identification and validation of inhibitors of the interaction between neuropilin receptor 1 and SARS-CoV-2 Spike protein. *bioRxiv*.
- PREMKUMAR, L., SEGOVIA-CHUMBEZ, B., JADI, R., MARTINEZ, D. R., RAUT, R., MARKMANN, A., CORNABY, C., BARTELT, L., WEISS, S., PARK, Y., EDWARDS, C. E., WEIMER, E., SCHERER, E. M., ROUPHAEL, N., EDUPUGANTI, S., WEISKOPF, D., TSE, L. V., HOU, Y. J., MARGOLIS, D., SETTE, A., COLLINS, M. H., SCHMITZ, J., BARIC, R. S. & DE SILVA, A. M. 2020. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Sci Immunol*, 5.
- QIAO, Y., WANG, X. M., MANNAN, R., PITCHIAYA, S., ZHANG, Y., WOTRING, J. W., XIAO, L., ROBINSON, D. R., WU, Y. M., TIEN, J. C., CAO, X., SIMKO, S. A., APEL, I. J., BAWA, P., KREGEL, S., NARAYANAN, S. P., RASKIND, G., ELLISON, S. J., PAROLIA, A., ZELENKA-WANG, S., MCMURRY, L., SU, F., WANG, R., CHENG, Y., DELEKTA, A. D., MEI, Z., PRETTO, C. D., WANG, S., MEHRA, R., SEXTON, J. Z. & CHINNAIYAN, A. M. 2020. Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2. *Proc Natl Acad Sci U S A*.
- RAHMAN, N., BASHARAT, Z., YOUSUF, M., CASTALDO, G., RASTRELLI, L. & KHAN, H. 2020. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2). *Molecules*, 25.
- RAIMONDI, C., BRASH, J. T., FANTIN, A. & RUHRBERG, C. 2016. NRP1 function and targeting in neurovascular development and

eye disease. *Prog Retin Eye Res*, 52, 64-83.

RIVA, L., YUAN, S., YIN, X., MARTIN-SANCHO, L., MATSUNAGA, N., BURGSTALLER-MUEHLBACHER, S., PACHE, L., DE JESUS, P. P., HULL, M. V., CHANG, M., CHAN, J. F.-W., CAO, J., POON, V. K.-M., HERBERT, K., NGUYEN, T.-T., PU, Y., NGUYEN, C., RUBANOV, A., MARTINEZ-SOBRILO, L., LIU, W.-C., MIORIN, L., WHITE, K. M., JOHNSON, J. R., BENNER, C., SUN, R., SCHULTZ, P. G., SU, A., GARCIA-SASTRE, A., CHATTERJEE, A. K., YUEN, K.-Y. & CHANDA, S. K. 2020. A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals. *bioRxiv*, 2020.04.16.044016.

ROBBIANI, D. F., GAEBLER, C., MUECKSCH, F., LORENZI, J. C. C., WANG, Z., CHO, A., AGUDELO, M., BARNES, C. O., GAZUMYAN, A., FINKIN, S., HAGGLOF, T., OLIVEIRA, T. Y., VIANT, C., HURLEY, A., HOFFMANN, H. H., MILLARD, K. G., KOST, R. G., CIPOLLA, M., GORDON, K., BIANCHINI, F., CHEN, S. T., RAMOS, V., PATEL, R., DIZON, J., SHIMELIOVICH, I., MENDOZA, P., HARTWEGER, H., NOGUEIRA, L., PACK, M., HOROWITZ, J., SCHMIDT, F., WEISBLUM, Y., MICHAILIDIS, E., ASHBROOK, A. W., WALTARI, E., PAK, J. E., HUEY-TUBMAN, K. E., KORANDA, N., HOFFMAN, P. R., WEST, A. P., JR., RICE, C. M., HATZIOANNOU, T., BJORKMAN, P. J., BIENIASZ, P. D., CASKEY, M. & NUSSENZWEIG, M. C. 2020. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature*, 584, 437-442.

ROSSI, A., DEVERAUX, Q., TURK, B. & SALI, A. 2004. Comprehensive search for cysteine cathepsins in the human genome. *Biol Chem*, 385, 363-72.

SHANG, J., WAN, Y., LUO, C., YE, G., GENG, Q., AUERBACH, A. & LI, F. 2020. Cell entry mechanisms of SARS-CoV-2. *Proc Natl Acad Sci U S A*, 117, 11727-11734.

SHIRATO, K., KAWASE, M. & MATSUYAMA, S. 2018. Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry. *Virology*, 517, 9-15.

SIMMONS, G., GOSALIA, D. N., RENNEKAMP, A. J., REEVES, J. D., DIAMOND, S. L. & BATES, P. 2005. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. *Proc Natl Acad Sci U S A*, 102, 11876-81.

SINGH, M., BANSAL, V. & FESCHOTTE, C. 2020. A single-cell RNA expression map of human coronavirus entry factors. *bioRxiv*.

SUBRAMANIAN, A., VERNON, K. A., SLYPER, M., WALDMAN, J., LUECKEN, M. D., GOSIK, K., DUBINSKY, D., CUOCO, M. S., KELLER, K., PURNELL, J., NGUYEN, L., DIONNE, D., ROZENBLATT-ROSEN, O., WEINS, A., REGEV, A. & GREKA, A. 2020. RAAS blockade, kidney disease, and expression of ACE2, the entry receptor for SARS-CoV-2, in kidney epithelial and endothelial cells.

UNIPROT KB - O14786 (NRP1\_HUMAN)

WALLS, A. C., TORTORICI, M. A., BOSCH, B. J., FRENZ, B., ROTTIER, P. J. M., DIMAIO, F., REY, F. A. & VEESLER, D. 2016. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. *Nature*, 531, 114-117.

WANG, Y., LIU, M. & GAO, J. 2020. Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions. *Proc Natl Acad Sci U S A*, 117, 13967-13974.

YAMAMOTO, M., KISO, M., SAKAI-TAGAWA, Y., IWATSUKI-HORIMOTO, K., IMAI, M., TAKEDA, M., KINOSHITA, N., OHMAGARI, N., GOHDA, J., SEMBA, K., MATSUDA, Z., KAWAGUCHI, Y., KAWAOKA, Y. & INOUE, J. I. 2020. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner. *Viruses*, 12.

YANG, N. & SHEN, H.-M. 2020. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19. *International Journal of Biological Sciences*, 16, 1724-1731.

YUAN, M., WU, N. C., ZHU, X., LEE, C. D., SO, R. T. Y., LV, H., MOK, C. K. P. & WILSON, I. A. 2020. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. *Science*, 368, 630-633.

ZANG, R., GOMEZ CASTRO, M. F., MCCUNE, B. T., ZENG, Q., ROTHLAUF, P. W., SONNEK, N. M., LIU, Z., BRULOIS, K. F., WANG, X., GREENBERG, H. B., DIAMOND, M. S., CIORBA, M. A., WHELAN, S. P. J. & DING, S. 2020. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. *Sci Immunol*, 5.

ZIEGLER, C. G. K., ALLON, S. J., NYQUIST, S. K., MBANO, I. M., MIAO, V. N., TZOUANAS, C. N., CAO, Y., YOUSIF, A. S., BALS, J., HAUSER, B. M., FELDMAN, J., MUUS, C., WADSWORTH, M. H., 2ND, KAZER, S. W., HUGHES, T. K., DORAN, B., GATTER, G. J., VUKOVIC, M., TALIAFERRO, F., MEAD, B. E., GUO, Z., WANG, J. P., GRAS, D., PLAISANT, M., ANSARI, M., ANGELIDIS, I., ADLER, H., SUCRE, J. M. S., TAYLOR, C. J., LIN, B., WAGHRAY, A., MITSIALIS, V., DWYER, D. F., BUCHHEIT, K. M., BOYCE, J. A., BARRETT, N. A., LAIDLAW, T. M., CARROLL, S. L., COLONNA, L., TKACHEV, V., PETERSON, C. W., YU, A., ZHENG, H. B., GIDEON, H. P., WINCHELL, C. G., LIN, P. L., BINGLE, C. D., SNAPPER, S. B., KROPSKI, J. A., THEIS, F. J., SCHILLER, H. B., ZARAGOSI, L. E., BARBRY, P., LESLIE, A., KIEM, H. P., FLYNN, J. L., FORTUNE, S. M., BERGER, B., FINBERG, R. W., KEAN, L. S., GARBER, M., SCHMIDT, A. G., LINGWOOD, D., SHALEK, A. K., ORDOVAS-MONTANES, J., LUNG-NETWORK@HUMANCELLATLAS.ORG, H. C. A. L. B. N. E. A. & NETWORK, H. C. A. L. B. 2020. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. *Cell*, 181, 1016-1035 e19.

**Event: 1847: Increased coronavirus production**

**Short Name: Increased SARS-CoV-2 production**

**Key Event Component**

| Process                                 | Object                                    | Action    |
|-----------------------------------------|-------------------------------------------|-----------|
| viral RNA genome replication            | viral RNA-directed RNA polymerase complex | increased |
| positive stranded viral RNA replication | viral RNA-directed RNA polymerase complex | increased |
| viral RNA genome packaging              | viral assembly compartment                | increased |
| mRNA transcription                      | ssRNA viral genome                        | increased |
| viral translation                       | ssRNA viral genome                        | increased |

**AOPs Including This Key Event**

| AOP ID and Name                                                                                                                                               | Event Type               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| <a href="#">Aop:379 - Increased susceptibility to viral entry and coronavirus production leading to thrombosis and disseminated intravascular coagulation</a> | MolecularInitiatingEvent |
| <a href="#">Aop:320 - Binding of viral S-glycoprotein to ACE2 receptor leading to acute respiratory distress associated mortality</a>                         | KeyEvent                 |
| <a href="#">Aop:406 - SARS-CoV-2 infection leading to hyperinflammation</a>                                                                                   | KeyEvent                 |
| <a href="#">Aop:407 - SARS-CoV-2 infection leading to pyroptosis</a>                                                                                          | KeyEvent                 |
| <a href="#">Aop:422 - Binding of SARS-CoV-2 to ACE2 in enterocytes leads to increased intestinal permeability resulting in GI disorders</a>                   | KeyEvent                 |
| <a href="#">Aop:430 - Sars-CoV-2 Interferon-I antiviral response antagonism and increased viral production leading to viral infection proliferation</a>       | KeyEvent                 |

**Stressors****Name**

Sars-CoV-2

**Biological Context****Level of Biological Organization**

Cellular

**Cell term****Cell term**

cell

**Organ term****Organ term**

organ

**Domain of Applicability****Taxonomic Applicability**

| Term         | Scientific Term | Evidence | Links                |
|--------------|-----------------|----------|----------------------|
| Homo sapiens | Homo sapiens    | High     | <a href="#">NCBI</a> |
| Mus musculus | Mus musculus    | Moderate | <a href="#">NCBI</a> |

Mustela putorius furo    Mustela putorius furo    Moderate    [NCBI](#)

## Life Stage Applicability

### Life Stage    Evidence

All life stages    High

## Sex Applicability

### Sex    Evidence

Unspecific    High

Broad mammalian host range has been demonstrated based on spike protein tropism for and binding to ACE2 [Conceicao *et al.* 2020; Wu *et al.* 2020] and cross-species ACE2 structural analysis [Damas *et al.* 2020]. No literature has been found on primary translation and molecular interactions of nsps in non-human host cells, but it is assumed to occur if the virus replicates in other species.

Very broad mammalian tropism: human, bat, cat, dog, civet, ferret, horse, pig, sheep, goat, water buffalo, cattle, rabbit, hamster, mouse

## Key Event Description

This KE1847 "Increase coronavirus production" deals with how the genome of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is translated, replicated, and transcribed in detail, and how the genomic RNA (gRNA) is packaged, and the virions are assembled and released from the cell.

Coronavirus is a class of viruses that have single-stranded positive-sense RNA genomes in their envelopes [D. Kim *et al.*]. The virus contains a 29.7 kB positive-sense RNA genome flanked by 5' and 3' untranslated regions of 265 and 342 nucleotides, respectively [E. J. Snijder *et al.*] that contain cis-acting secondary RNA structures essential for RNA synthesis [N. C. Huston *et al.*]. The genome just prior to the 5' end contains the transcriptional regulatory sequence leader (TRS-L) [C.J. Budzylowicz *et al.*]. The SARS-CoV genome is polycistronic and contains 14 open reading frames (ORFs) that are expressed by poorly understood mechanisms [E. J. Snijder *et al.*]. Preceding each ORF there are other TRSs called the body TRS (TRS B). The 5' two-thirds of the genome contains two large, overlapping, nonstructural ORFs and the 3' third contains the remainder ORFs [H. Di *et al.*]. Genome expression starts with the translation of two large ORFs of the 5' two-thirds: ORF1a of 4382 amino acids and ORF1ab of 7073 amino acid that occurs via a programmed (-1) ribosomal frameshifting [E. J. Snider *et al.*], yielding pp1a and pp1ab. These two polypeptides are cleaved into 16 subunits by two viral proteinases encoded by ORF1a, nsp3, and nsp5 that contain a papain-like protease domain and a 3C-like protease domain [M. D. Sacco *et al.*]. The processing products are a group of replicative enzymes, named nsp1-nsp16, that assemble into a viral replication and transcription complex (RTC) associated with membranes of endoplasmic reticulum (ER) with the help of various membrane-associated viral proteins [S. Klein *et al.*, E. J. Snijder *et al.*, P. V'Kovski, *et al.*]. Besides replication, which yields the positive-sense gRNA, the replicase also mediates transcription leading to the synthesis of a nested set of subgenomic (sg) mRNAs to express all ORFs downstream of ORF1b that encode structural and accessory viral proteins. These localize to the 3' one-third of the genome, as stated above, and result in a 3' coterminal nested set of 7–9 mRNAs that share ~70–90 nucleotide (nt) in the 5' leader and that is identical to the 5' end of the genome [P. Liu, and J. Leibowitz]. sgRNAs encode conserved structural proteins (spike protein [S], envelope protein [E], membrane protein [M], and nucleocapsid protein [N]), and several accessory proteins. SARS-CoV-2 is known to have at least six accessory proteins (3a, 6, 7a, 7b, 8, and 10). Overall the virus is predicted to express 29 proteins [D. Kim *et al.*]. The gRNA is packaged by the structural proteins to assemble progeny virions.

### Viral translation:

SARS-CoV-2 is an enveloped virus with a single-stranded RNA genome of ~30 kb, sequence orientation in a 5' to 3' direction typical of positive sense and reflective of the resulting mRNA [D. Kim *et al.*]. The SARS-CoV-2 genome contains a 5'-untranslated region (UTR; 265 bp), ORF1ab (21,289 bp) holding two overlapping open reading frames (13,217 bp and 21,289 bp, respectively) that encode two polyproteins [D. Kim *et al.*]. Other elements of the genome include are shown below [V. B. O'Leary *et al.*]. **The first event upon cell entry is the primary translation of the ORF1a and ORF1b gRNA to produce non-structural proteins (nsps).**

This is completely dependent on the translation machinery of the host cell. Due to fewer rare "slow-codons", SARS-CoV-2 may have a higher protein translational rate, and therefore higher infectivity compared to other coronavirus groups [V. B. O'Leary *et al.*]. The ORF1a produces polypeptide 1a (pp1a, 440–500 kDa) that is cleaved into nsp-1 through nsp-11. A -1 ribosome frameshift occurs immediately upstream of the ORF1a stop codon, to allow translation through ORF1b, yielding 740–810 kDa polypeptide pp1ab, which is cleaved into 15 nsps [D. Kim *et al.*]. Two overlapping ORFs, ORF1a and ORF1b, generate continuous polypeptides, which are cleaved into a total of 16 so-called nsps [Y Finkel *et al.*]. Functionally, there are five proteins from pp1ab (nsp-12 through nsp-16) as nsp-1-11 are duplications of the proteins in pp1a due to the ORF overlap. The pp1a is approximately 1.4–2.2 times more expressed than pp1ab. After translation, the polyproteins are cleaved by viral proteases nsp3 and nsp5. Nsp5 protease can be referred to as 3C-like protease (3CL<sup>pro</sup>) or as main protease (M<sup>pro</sup>), as it cleaves the majority of the polyprotein cleavage sites. [H.A. Hussein *et al.*] Nsp1 cleavage is quick and nsp1 associates with host cell ribosomes and results in host cellular shutdown, suppressing host gene expression [M. Thoms *et al.*]. Fifteen proteins, nsp2–16 constitute the viral RTC. They are targeted to defined subcellular locations and establish a network with host cell factors. Nsp2–11 remodel host membrane architecture, mediate host immune evasion and provide cofactors for replication, whilst nsp12–16 contain the core enzymatic functions involved in RNA synthesis, modification and proofreading [P. V'Kovski *et al.*]. nsp-7 and nsp-8 form a complex priming the RNA-dependent RNA polymerase (RdRp or RTC) - nsp-12. nsp14 provides a 3'–5' exonuclease activity providing RNA proofreading function. Nsp-10 composes the RNA capping machinery nsp-9. nsp13 provides the RNA 5'-triphosphatase activity. Nsp-14 is a N7-methyltransferase and nsp-16 the 2'-O-methyltransferase. Many of the nsps have multiple functions and many viral proteins are involved in innate immunity inhibition. Nsp-3 is involved in vesicle formation along with nsp-4 and nsp-6 where viral replication occurs. Interactions between SARS-CoV-2 proteins and human RNAs thwart the IFN response upon infection: nsp-16 binds to U1 and U2 splicing RNAs to suppress global mRNA splicing; nsp-1 binds to 40S ribosomal RNA in the mRNA entry channel of the ribosome to inhibit host mRNA translation; nsp-8 and nsp-9 bind to the 7SL RNA to block protein trafficking to the cell membrane [A. K. Banerjee *et al.*]. Xia *et al.* [H. Xia *et al.*] found that nsp-6 and nsp-13 antagonize IFN-I production via distinct mechanisms: nsp-6 binds TANK binding kinase 1 (TBK1) to suppress interferon regulatory factor 3 (IRF3) phosphorylation, and nsp-13 binds and blocks TBK1

phosphorylation.

### Viral transcription and replication:

Viral transcription and replication occur at the viral replication organelle (RO) [E. J. Snijder *et al.*]. The RO is specifically formed during infection by reshaping ER and other membranes, giving rise to small spherular invaginations, and large vesiculotubular clusters, consisting of single- and/or double-membrane vesicles (DMV), convoluted membranes (CM) and double-membrane spherules invaginating from the ER [S. Klein *et al.*, E. J. Snijder *et al.*]. There is some evidence that DMV accommodate viral replication which is based on radiolabelling viral RNA with nucleoside precursor ([5-<sup>3</sup>H]uridine) and detection by EM autoradiography [E. J. Snijder *et al.*].

Viral replicative proteins and specific host factors are recruited to ROs [E. J. Snijder *et al.*]. RNA viral genome is transcribed into messenger RNA by the viral RTC [P. Ahlquist *et al.*]. Viral RTC act in combination with other viral and host factors involved in selecting template RNAs, elongating RNA synthesis, differentiating genomic RNA replication from mRNA transcription, modifying product RNAs with 5' caps or 3' polyadenylate [P. Ahlquist *et al.*]. Positive-sense (messenger-sense) RNA viruses replicate their genomes through negative-strand RNA intermediates [M. Schwartz *et al.*]. The intermediates comprise full-length negative-sense complementary copies of the genome, which functions as templates for the generation of new positive-sense gRNA, and a nested set of sg mRNAs that lead to the expression of proteins encoded in all ORFs downstream of ORF1b. The transcription of coronaviruses is a discontinuous process that produces nested 3' and 5' co-terminal sgRNAs. Of note, the synthesis of sg mRNAs is not exclusive to the order *Nidovirales* but a discontinuous minus-strand synthesis strategy to produce a nested set of 3' co-terminal sg mRNAs with a common 5' leader in infected cells are unique features of the *coronaviruses* and *arteriviruses* [W. A. Miller and G. Koev.]. Of note, the produced genomic RNA represents a small fraction of the total vRNA [N. S. Ogando *et al.*].

The discontinuous minus-strand synthesis of a set of nested sg mRNAs happens during the synthesis of the negative-strand RNA, by an interruption mechanism of the RTC as it reads the TRS-B preceding each gene in the 3' one-third of the viral genome [I. Sola, F. Almazan *et al.*, I. Sola, J. L. Moreno, *et al.*]. The synthesis of the negative-strand RNA stops and is re-initiated at the TRS-L of the genome sequence close from the 5' end of the genome [H. Di *et al.*]. Therefore, the mechanism by which the leader sequence is added to the 5' end requires that the RTC switches template by a jumping mechanism. This interruption process involves the interaction between complementary TRSs of the nascent negative-strand RNA TRS-B and the positive-strand gRNA at the positive-sense TRS-L. The TRS-B site has a 7-8 bp conserved core sequence (CS) that facilitates RTC template switching as it hybridizes with a near complementary CS in the TRS-L [I. Sola, F. Almazan *et al.*, I. Sola, J. L. Moreno, *et al.*]. Upon re-initiation of RNA synthesis at the TRS-L region, a negative-strand copy of the leader sequence is added to the nascent RNA to complete the synthesis of negative-strand sgRNAs. This means that all sg mRNAs as well as the genomic RNA share a common 5' sequence, named leader sequence [X. Zhang *et al.*]. This programmed template switching leads to the generation of sg mRNAs with identical 5' and 3' sequences, but alternative central regions corresponding to the beginning of each structural ORF [I. Sola *et al.* 2015, S. G. Sawicki *et al.*, Y. Yang *et al.*]. Of note, the existence of TRSs also raises the possibility that these sites are at the highest risk of recombining through TRS-B mediated template switching [Y. Yang]. The set of sg mRNAs is then translated to yield 29 identified different proteins [F. Wu *et al.*], although many papers have identified additional ORFs [D. Kim *et al.*, Y. Finkel *et al.*, A. Vandelli *et al.*]. The translation of the linear single-stranded RNA conducts to the generation of the following proteome: 4 are structural proteins, S, N, M, and E; 16 proteins nsp: the first 11 are encoded in ORF1a whereas the last 5 are encoded in ORF1ab. In addition, 9 accessory proteins named ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF9b, ORF9c, and ORF10 have been identified [F. Wu *et al.*]. At the beginning of infection, there is the predominant expression of the nsp that result from ORF1a and ORF1ab, however, at 5 hpi, the proteins encoded by the 5' last third are found in higher amounts, and the nucleoprotein is the protein found in higher levels [Y. Finkel *et al.*].

### Viral assembly:

The final step of viral production requires virion assembly and this process is not well explored for SARS-CoV-2. For example, the role of the structural proteins of SARS-CoV-2 in virus assembly and budding is not known. In general, all beta-coronavirus structural proteins assemble at the endoplasmic reticulum (ER)-to-Golgi compartment [J. R. Cohen *et al.*, A. Perrier *et al.*] and viral assembly requires two steps: Genome packaging which is a process in which the SARS-CoV-2 gRNA must be coated by the viral protein nucleoprotein (N) protein, forming viral ribonucleoprotein (vRNPs) complexes, before being selectively packaged into progeny virions [P. V'kovski *et al.*], a step in which vRNPs bud into the lumen of the ER and the ER-Golgi intermediate compartment (ERGIC) [N. S. Ogando *et al.*]. This results in viral particles enveloped with host membranes containing viral M, E, and S transmembrane structural proteins that need to be released from the cell.

SARS-CoV-2 gRNA packaging involves the N protein. The N protein of human coronaviruses is highly expressed in infected cells. It is considered a multifunctional protein, promoting efficient sub-genomic viral RNA transcription, viral replication, virion assembly, and interacting with multiple host proteins [P. V'kovski *et al.*, D. E. Gordon *et al.*, R. McBride, and M. van Zyl, B. C.]. In relation to transcription and replication, the N protein could provide a cooperative mechanism to increase protein and RNA concentrations at specific localizations S. Alberti, and S. Carra, S. F. Banani *et al.*, and this way organize viral transcription. Five studies have shown that N protein undergoes liquid-liquid phase separation (LLPS) *in vitro* [A. Savastano *et al.*, H. Chen *et al.*, C. Iserman *et al.*, T. M. Perdikari *et al.*, J. Cubuk *et al.*], dependent on its C-terminal domain (CTD) [H. Chen *et al.*]. It has been hypothesised that N could be involved in replication close to the ER and in packaging of gRNA into vRNPs near the ERGIC where genome assembly is thought to take place [A. Savastano *et al.*], but so far this is still speculative. Phosphorylation of N could adjust the physical properties of condensates differentially in ways that could accommodate the two different functions of N: transcription and progeny genome assembly [A. Savastano *et al.*, C. Iserman *et al.*, C. R. Carlson *et al.*].

The ERGIC constitutes the main assembly site of coronaviruses [S. Klein *et al.*, E. J. Snijder *et al.*, L. Mendonca *et al.*] and budding events have been seen by EM studies. For SARS-CoV-2, virus-budding was mainly clustered in regions with a high vesicle density and close to ER- and Golgi-like membrane arrangements [S. Klein *et al.*, E. J. Snijder *et al.*, L. Mendonca *et al.*]. The ectodomain of S trimers were found facing the ERGIC lumen and not induce membrane curvature on its own, therefore proposing that vRNPs and spike trimers [S. Klein *et al.*].

Finally, it has been shown that SARS-CoV-2 virions de novo formed traffic to lysosomes for unconventional egress by Arl8b-dependent lysosomal exocytosis [S. Ghosh *et al.*]. This process results in lysosome deacidification, inactivation of lysosomal degradation enzymes, and

disruption of antigen presentation [S. Ghosh *et al.*].

## How it is Measured or Detected

### Viral translation:

SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation [Schubert *et al.* 2020]

- Sucrose pelleting binding assay to verify Nsp1–40S complex formation
- In vivo translation assay
- Transient expression of FLAG-Nsp1 in HeLa cells and puromycin incorporation assay

SARS-CoV-2 disrupts splicing, translation, and protein trafficking [Banerjee *et al.* 2020]

- SARS-CoV-2 viral protein binding to RNA
- Interferon stimulation experiments
- Splicing assessment experiments
- IRF7-GFP splicing reporter, 5EU RNA labeling, capture of biotinylated 5EU labeled RNA

Membrane SUNSET assay for transport of plasma membrane proteins to the cell surface

### Viral transcription:

The mRNA transcripts are detected by the real-time reverse transcription-PCR (RT-PCR) assay. Several methods targeting the mRNA transcripts have been developed, which includes the RT-PCR assays targeting RdRp/helicase (Hel), spike (S), and nucleocapsid (N) genes of SARS-CoV-2 [Chan *et al.*]. RT-PCR assays detecting SARS-CoV-2 RNA in saliva include quantitative RT-PCR (RT-qPCR), direct RT-qPCR, reverse transcription-loop-mediated isothermal amplification (RT-LAMP) [Nagura-Ikeda M, *et al.*]. The viral mRNAs are reverse-transcribed with RT, followed by the amplification by PCR.

### Viral replication:

viral replication is measured by RT-qPCR in infected cells, formation of liquid organelles is assessed in vitro reconstitution systems and in infected cells. Labelling by radioactive nucleosides.

### Viral production:

Plaque assays, infectivity assays, RT-qPCR to detect viral RNA in released virions, sequencing to detect mutations in the genome, electron microscopy.

## References

1. D. Kim *et al.*, The Architecture of SARS-CoV-2 Transcriptome. *Cell* **181**, 914-921 e910 (2020).
2. E. J. Snijder *et al.*, Unique and Conserved Features of Genome and Proteome of SARS-coronavirus, an Early Split-off From the Coronavirus Group 2 Lineage. *Journal of Molecular Biology* **331**, 991-1004 (2003).
3. N. C. Huston *et al.*, Comprehensive in vivo secondary structure of the SARS-CoV-2 genome reveals novel regulatory motifs and mechanisms. *Mol Cell* **81**, 584-598 e585 (2021).
4. C. J. Budzylowicz, S. P. Wilczynski, S. R. Weiss, Three intergenic regions of coronavirus mouse hepatitis virus strain A59 genome RNA contain a common nucleotide sequence that is homologous to the 3' end of the viral mRNA leader sequence. *J Virol* **53**, 834-840 (1985).
5. H. Di, A. A. McIntyre, M. A. Brinton, New insights about the regulation of Nidovirus subgenomic mRNA synthesis. *Virology* **517**, 38-43 (2018).
6. M. D. Sacco *et al.*, Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L. *Sci Adv* **6**, (2020).
7. S. Klein *et al.*, SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography. *BioRxiv*, (2020).
8. E. J. Snijder *et al.*, A unifying structural and functional model of the coronavirus replication organelle: Tracking down RNA synthesis. *PLoS Biol* **18**, e3000715 (2020).
9. P. V'Kovski, A. Kratzel, S. Steiner, H. Stalder, V. Thiel, Coronavirus biology and replication: implications for SARS-CoV-2. *Nat Rev Microbiol*, (2020).
10. P. Liu, J. Leibowitz, in *Molecular Biology of the SARS-Coronavirus*. (2010), chap. Chapter 4, pp. 47-61.
11. V. B. O'Leary, O. J. Dolly, C. Hoschl, M. Cerna, S. V. Ovsepian, Unpacking Pandora From Its Box: Deciphering the Molecular Basis of the SARS-CoV-2 Coronavirus. *Int J Mol Sci* **22**, (2020).
12. Y. Finkel *et al.*, The coding capacity of SARS-CoV-2. *Nature* **589**, 125-130 (2021).

13. H. A. Hussein, R. Y. A. Hassan, M. Chino, F. Febbraio, Point-of-Care Diagnostics of COVID-19: From Current Work to Future Perspectives. *Sensors (Basel)* **20**, (2020).
14. M. Thoms *et al.*, Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. *Science* **369**, 1249-1255 (2020).
15. A. K. Banerjee *et al.*, SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses. *Cell* **183**, 1325-1339 e1321 (2020).
16. H. Xia *et al.*, Evasion of Type I Interferon by SARS-CoV-2. *Cell Rep* **33**, 108234 (2020).
17. P. Ahlquist, RNA-dependent RNA polymerases, viruses, and RNA silencing. *Science* **296**, 1270-1273 (2002).
18. M. Schwartz *et al.*, A Positive-Strand RNA Virus Replication Complex Parallels Form and Function of Retrovirus Capsids. *Molecular Cell* **9**, 505-514 (2002).
19. W. A. Miller, G. Koev, Synthesis of subgenomic RNAs by positive-strand RNA viruses. *Virology* **273**, 1-8 (2000).
20. N. S. Ogando *et al.*, SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology. *J Gen Virol* **101**, 925-940 (2020).
21. I. Sola, F. Almazan, S. Zuniga, L. Enjuanes, Continuous and Discontinuous RNA Synthesis in Coronaviruses. *Annu Rev Virol* **2**, 265-288 (2015).
22. I. Sola, J. L. Moreno, S. Zuniga, S. Alonso, L. Enjuanes, Role of nucleotides immediately flanking the transcription-regulating sequence core in coronavirus subgenomic mRNA synthesis. *J Virol* **79**, 2506-2516 (2005).
23. X. Zhang, C. L. Liao, M. M. Lai, Coronavirus leader RNA regulates and initiates subgenomic mRNA transcription both in trans and in cis. *J Virol* **68**, 4738-4746 (1994).
24. S. G. Sawicki, D. L. Sawicki, S. G. Siddell, A contemporary view of coronavirus transcription. *J Virol* **81**, 20-29 (2007).
25. Y. Yang, W. Yan, B. Hall, X. Jiang, Characterizing transcriptional regulatory sequences in coronaviruses and their role in recombination. *bioRxiv*, (2020).
26. F. Wu *et al.*, A new coronavirus associated with human respiratory disease in China. *Nature* **579**, 265-269 (2020).
27. A. Vandelli *et al.*, Structural analysis of SARS-CoV-2 genome and predictions of the human interactome. *Nucleic Acids Res* **48**, 11270-11283 (2020).
28. J. R. Cohen, L. D. Lin, C. E. Machamer, Identification of a Golgi complex-targeting signal in the cytoplasmic tail of the severe acute respiratory syndrome coronavirus envelope protein. *J Virol* **85**, 5794-5803 (2011).
29. A. Perrier *et al.*, The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal. *J Biol Chem* **294**, 14406-14421 (2019).
30. D. E. Gordon *et al.*, A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature* **583**, 459-468 (2020).
31. R. McBride, M. van Zyl, B. C. Fielding, The coronavirus nucleocapsid is a multifunctional protein. *Viruses* **6**, 2991-3018 (2014).
32. S. Alberti, S. Carra, Quality Control of Membraneless Organelles. *Journal of Molecular Biology* **430**, 4711-4729 (2018).
33. S. F. Banani, H. O. Lee, A. A. Hyman, M. K. Rosen, Biomolecular condensates: organizers of cellular biochemistry. *Nature Reviews Molecular Cell Biology* **18**, 285-298 (2017).
34. A. Savastano, A. I. de Opakua, M. Rankovic, M. Zweckstetter, Nucleocapsid protein of SARS-CoV-2 phase separates into RNA-rich polymerase-containing condensates. (2020).
35. H. Chen *et al.*, Liquid-liquid phase separation by SARS-CoV-2 nucleocapsid protein and RNA. *Cell Res*, (2020).
36. C. Iserman *et al.*, Specific viral RNA drives the SARS CoV-2 nucleocapsid to phase separate. *bioRxiv*, (2020).
37. T. M. Perdikari *et al.*, SARS-CoV-2 nucleocapsid protein undergoes liquid-liquid phase separation stimulated by RNA and partitions into phases of human ribonucleoproteins. *bioRxiv*, (2020).
38. J. Cubuk *et al.*, The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. *bioRxiv*, (2020).
39. C. Iserman *et al.* (Cold Spring Harbor Laboratory, 2020).
40. C. R. Carlson *et al.*, Phosphoregulation of phase separation by the SARS-CoV-2 N protein suggests abiophysical basis for its dual functions. *Molecular Cell*, (2020).
41. L. Mendonca *et al.*, SARS-CoV-2 Assembly and Egress Pathway Revealed by Correlative Multi-modal Multi-scale Cryo-imaging. *bioRxiv*, (2020).
42. S. Ghosh *et al.*, beta-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway. *Cell* **183**, 1520-1535 e1514 (2020).

43. Schubert, K., Karousis, E.D., Jomaa, A. *et al.* SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation. *Nat Struct Mol Biol* **27**, 959–966 (2020).
44. Chan, Jasper Fuk-Woo *et al.* Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated *In Vitro* and with Clinical Specimens. *J Clin Microbiol.* 2020;58(5):e00310-20. doi:10.1128/JCM.00310-20
45. Nagura-Ikeda M, Imai K, Tabata S, *et al.* Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19. *J Clin Microbiol.* 2020;58(9):e01438-20. doi:10.1128/JCM.01438-20
46. Conceicao C, Thakur N, Human S, Kelly JT, Logan L, Bialy D, *et al.* (2020) The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins. *PLoS Biol* **18**(12): e3001016. <https://doi.org/10.1371/journal.pbio.3001016>
47. Damas J, Hughes GM, Keough KC, Painter CA, Persky NS, Corbo M, Hiller M, Koepfli KP, Pfenning AR, Zhao H, Genereux DP, Swofford R, Pollard KS, Ryder OA, Nweeia MT, Lindblad-Toh K, Teeling EC, Karlsson EK, Lewin HA. Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates. *Proc Natl Acad Sci U S A.* 2020 Sep 8;117(36):22311-22322. doi: 10.1073/pnas.2010146117. Epub 2020 Aug 21. PMID: 32826334; PMCID: PMC7486773.

## List of Key Events in the AOP

### [Event: 1869: Down-regulation of protective oxidative stress response](#)

**Short Name:** Response to ROS

#### Key Event Component

| Process                               | Object                  | Action    |
|---------------------------------------|-------------------------|-----------|
| cellular response to oxidative stress | reactive oxygen species | increased |
| response to reactive oxygen species   | reactive oxygen species | increased |

#### AOPs Including This Key Event

| AOP ID and Name                                                                                                                                                                    | Event Type |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| <a href="#">Aop:379 - Increased susceptibility to viral entry and coronavirus production leading to thrombosis and disseminated intravascular coagulation</a>                      | KeyEvent   |
| <a href="#">Aop:406 - SARS-CoV-2 infection leading to hyperinflammation</a>                                                                                                        | KeyEvent   |
| <a href="#">Aop:407 - SARS-CoV-2 infection leading to pyroptosis</a>                                                                                                               | KeyEvent   |
| <a href="#">Aop:377 - Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Acute Respiratory Distress Syndrome (ARDS) and Multiple Organ Dysfunction (MOD)</a> | KeyEvent   |

#### Stressors

##### Name

Stressor:624 SARS-CoV-2

#### Biological Context

##### Level of Biological Organization

Cellular

#### Cell term

##### Cell term

cell

**Organ term****Organ term**

organ

**Domain of Applicability****Taxonomic Applicability**

| Term         | Scientific Term | Evidence | Links                |
|--------------|-----------------|----------|----------------------|
| Homo sapiens | Homo sapiens    | High     | <a href="#">NCBI</a> |

**Life Stage Applicability**

| Life Stage      | Evidence |
|-----------------|----------|
| All life stages | High     |

**Sex Applicability**

| Sex        | Evidence |
|------------|----------|
| Unspecific | High     |

Response to ROS occurs in many cell types and tissues in all life stages and the broad range of mammals.

**Key Event Description**

Oxidative stress is caused by an imbalance between the production of reactive oxygen and the detoxification of reactive intermediates. Reactive intermediates such as peroxides and free radicals can be very damaging to many parts of cells such as proteins, lipids, and DNA. Severe oxidative stress can trigger apoptosis and necrosis. [Ref. IPA, NRF2-mediated Oxidative Stress Response, version60467501, release date: 2020-11-19]

The cellular defence/defense response to oxidative stress includes induction of detoxifying enzymes and antioxidant enzymes. Nuclear factor-erythroid 2-related factor 2 (Nrf2) binds to the antioxidant response elements (ARE) within the promoter of these enzymes and activates their transcription. Inactive Nrf2 is retained in the cytoplasm by association with an actin-binding protein Keap1. Upon exposure of cells to oxidative stress, Nrf2 is phosphorylated in response to the protein kinase C, phosphatidylinositol 3-kinase and MAP kinase pathways. After phosphorylation, Nrf2 translocates to the nucleus, binds AREs, and transactivates detoxifying enzymes and antioxidant enzymes, such as glutathione S-transferase, cytochrome P450, NAD(P)H quinone oxidoreductase, heme oxygenase, and superoxide dismutase. [Ref. IPA, NRF2-mediated Oxidative Stress Response, version60467501, release date: 2020-11-19]

Nrf2, a master regulator of oxidative stress through enhanced expression of anti-oxidant genes of glutathione and thioredoxin-antioxidant systems, has anti-inflammatory, anti-apoptotic, and antioxidant effects. Dimethyl fumarate (DMF), an activator of Nrf2, can decrease inflammation and reactive oxygen species (ROS) through the inhibition of NF-kappaB by inducing anti-oxidant enzymes [Hassan et al., MED ARCH. 2020 APR; 74(2): 134-138] [Timpani et al., Pharmaceuticals 2021, 14, 15.].

**How it is Measured or Detected**

Oxidative stress can be measured as follows:

1. Direct detection of reactive oxygen species (ROS)

ROS can be detected by intracellular ROS assay, *in vitro* ROS/RNS assay. Nitric oxide can be detected in intracellular nitric oxide assay.

Hydroxyl, peroxy, or other ROS can be measured using a fluorescence probe, 2', 7'-Dichlorodihydrofluorescein diacetate (DCFH-DA), at fluorescence detection at 480 nm/530 nm.

Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) can be detected with a colorimetric probe, which reacts with H<sub>2</sub>O<sub>2</sub> in a 1:1 stoichiometry to produce a bright pink colored product, followed by the detection with a standard colorimetric microplate reader with a filter in the 540-570 nm range.

2. Measurement of anti-oxidants

The level of catalase, glutathione, or superoxide dismutase can be measured as anti-oxidants. Catalase is an anti-oxidative enzyme that catalyses the resolution of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) into H<sub>2</sub>O and O<sub>2</sub>. The chemiluminescence or fluorescence of HRP catalytic reaction can be detected with residual H<sub>2</sub>O<sub>2</sub> and probes (DHBS+AAP, or ADHP (10-Acetyl-3, 7-dihydroxyphenoxazine)).

Anti-oxidant capacity is also one of the oxidative stress markers. Oxygen radical antioxidant capacity (ORAC), hydroxyl radical antioxidant capacity (HORAC), total antioxidant capacity (TAC), the cell-based exogenous antioxidant assay can be used for measuring the antioxidant capacity.

### 3. Detection of damages in protein, lipid, DNA or RNA

Oxidation of protein can be measured by the detection of protein carbonyl content (PCC), 3-nitrotyrosine, advanced oxidation protein products, or BPDE protein adduct.

DNA oxidation can be detected with 8-oxo-dG / 8-hydroxy-2'-deoxyguanosine (8-OHdG) by ELISA.

Lipid peroxides decompose to form malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), natural bi-products of lipid peroxidation. Lipid peroxidation can be monitored by thiobarbituric acid (TBA) reactive substances in biological samples. MDA and TBA form MDA-TBA adduct in a 1:2 stoichiometry and detected by colorimetric or fluorometric measurement.

## References

1. Hassan SM, Jawad MJ, Ahjel SW, Singh RB, Singh J, Awad SM, Hadi NR. The Nrf2 Activator (DMF) and Covid-19: Is there a Possible Role? *Med Arch*. 2020 Apr;74(2):134-138. doi: 10.5455/medarh.2020.74.134-138. PMID: 32577056; PMCID: PMC7296400.
2. Timpani CA, Rybalka E. Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19. *Pharmaceuticals*. 2021; 14(1):15. <https://doi.org/10.3390/ph14010015>
3. Chepelev, N.L.; Kennedy, D.A.; Gagné, R.; White, T.; Long, A.S.; Yauk, C.L., White, P.A. HPLC Measurement of the DNA Oxidation Biomarker, 8-oxo-7,8-dihydro-2'-deoxyguanosine, in Cultured Cells and Animal Tissues. *J Vis Exp* **2015**, e52697-e52697 [PMID: 26273842 DOI: 10.3791/52697]
4. Jackson, A.F.; Williams, A.; Recio, L.; Waters, M.D.; Lambert, I.B., Yauk, C.L. Case study on the utility of hepatic global gene expression profiling in the risk assessment of the carcinogen furan. *Toxicol Appl Pharmacol* **2014**, 274, 63-77 [PMID: 24183702 DOI: 10.1016/j.taap.2013.10.019]
5. Lee, D. Y., Kang, S., Lee, Y., Kim, J. Y., Yoo, D., Jung, W., . . . Jon, S. (2020). PEGylated Bilirubin-coated Iron Oxide Nanoparticles as a Biosensor for Magnetic Relaxation Switching-based ROS Detection in Whole Blood. *Theranostics*, 10(5), 1997-2007. doi:10.7150/thno.39662
6. Ashoka, A. H., Ali, F., Tiwari, R., Kumari, R., Pramanik, S. K., & Das, A. (2020). Recent Advances in Fluorescent Probes for Detection of HOCl and HNO. *ACS omega*, 5(4), 1730-1742. doi:10.1021/acsomega.9b03420

## Event: 1845: Coagulation

### Short Name: Coagulation

### AOPs Including This Key Event

| AOP ID and Name                                                                                                                                               | Event Type |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| <a href="#">Aop:379 - Increased susceptibility to viral entry and coronavirus production leading to thrombosis and disseminated intravascular coagulation</a> | KeyEvent   |

## Stressors

### Name

Sars-CoV-2

## Biological Context

### Level of Biological Organization

Cellular

**Cell term****Cell term**

blood cell

**Organ term****Organ term**

blood plasma

**Domain of Applicability****Taxonomic Applicability**

| Term         | Scientific Term | Evidence | Links                |
|--------------|-----------------|----------|----------------------|
| Homo sapiens | Homo sapiens    | Moderate | <a href="#">NCBI</a> |

**Life Stage Applicability**

| Life Stage      | Evidence |
|-----------------|----------|
| All life stages | Moderate |

**Sex Applicability**

| Sex        | Evidence |
|------------|----------|
| Unspecific | Moderate |

Homo sapiens

**Key Event Description**

Coagulation is a process that responds to injury by the rapid formation of a clot. Activation of coagulation factor proteins are involved in coagulation. In the extrinsic pathway, platelets, upon the contact with collagen in the injured blood vessel wall, release thromboxane A2 (TXA2) and adenosine 2 phosphates (ADP), leading to the clot formation. Extravascular tissue factor (TF) binds to plasma factor VIIa (FVIIa) and promotes the activation of FXa. Activated FXa assembles with cofactors FVa and FVIIIa on the surface of aggregated platelets, which lead to generation of thrombin (FIIa). Thrombin catalyzes the production of fibrin (FG) which creates a clot.

The binding of prekallikrein and high-molecular weight kininogen activate FXIIa in the intrinsic pathway.

Many regulators are involved in coagulation system. Plasmin is one of the modulators required for dissolution of the fibrin clot. Plasmin is activated by tissue plasminogen activator (tPA) and urokinase plasminogen activation (uPA). SERPINS inhibit thrombin, plasmin and tPA. For example, SERPINE1 or plasminogen activator inhibitor-1 (PAI-1) inhibits tPA/uPA and results in hypofibrinolysis [Bernard I, et al. *Viruses*. 2021; 13(1):29.]. In addition, SERPING1 inhibits FXII, and thus down-regulation of SERPING1 lifts suppression of FXII of the intrinsic coagulation cascade [Garvin et al. *eLife* 2020;9:e59177]. Protein C, protein S and thrombomodulin degrade FVa and FVIIIa. [Ref. IPA, Coagulation System, version60467501, release date: 2020-11-19]

**How it is Measured or Detected**

Coagulation and inflammatory parameters are measured in COVID-19 patients [Di Nisio et al. 2021]. Coagulation parameters include platelet count, prothrombin time, activated partial thromboplastin time, D-dimer, fibrinogen, antithrombin III [Di Nisio et al. 2021]. These parameters are measured in the blood.

**In vitro systems**

Whole human blood model for testing the activation of coagulation and complement system, as well as clot formation [Ekstrand-Hammarström, B. et al. *Biomaterials* 2015, 51, 58-68, Ekdahl, K.N., et al. *Nanomedicine: Nanotechnology, Biology and Medicine* 2018, 14, 735-744, Ekdahl, K.N., et al. *Science and Technology of Advanced Materials*, 20:1, 688-698,]

**References**

1. Bernard I, Limonta D, Mahal LK, Hobman TC. Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19. *Viruses*. 2021; 13(1):29. DOI: <https://doi.org/10.3390/v13010029>
2. Garvin et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. *eLife* 2020;9:e59177. DOI: <https://doi.org/10.7554/eLife.59177>
3. Di Nisio, Marcello et al. Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19 *European Journal of*

Internal Medicine, Volume 83, 34 - 38 DOI: <https://doi.org/10.1016/j.iejim.2020.10.020>

4. Ekstrand-Hammarström, B.; Hong, J.; Davoodpour, P.; Sandholm, K.; Ekdahl, K.N.; Bucht, A.; Nilsson, B. TiO<sub>2</sub> nanoparticles tested in a novel screening whole human blood model of toxicity trigger adverse activation of the kallikrein system at low concentrations. *Biomaterials* 2015, 51, 58-68 DOI:<https://doi.org/10.1016/j.biomaterials.2015.01.031>
5. Ekdahl, K.N.; Davoodpour, P.; Ekstrand-Hammarström, B.; Fromell, K.; Hamad, O.A.; Hong, J.; Bucht, A.; Mohlin, C.; Seisenbaeva, G.A.; Kessler, V.G.; Nilsson, B. Contact (kallikrein/kinin) system activation in whole human blood induced by low concentrations of  $\alpha$ -Fe<sub>2</sub>O<sub>3</sub> nanoparticles. *Nanomedicine: Nanotechnology, Biology and Medicine* 2018, 14, 735-744 [DOI: <https://doi.org/10.1016/j.nano.2017.12.008>]
6. Kristina N Ekdahl, Karin Fromell, Camilla Mohlin, Yuji Teramura & Bo Nilsson (2019) A human whole-blood model to study the activation of innate immunity system triggered by nanoparticles as a demonstrator for toxicity, *Science and Technology of Advanced Materials*, 20:1, 688-698, DOI: 10.1080/14686996.2019.1625721

## List of Adverse Outcomes in this AOP

### Event: 1846: Thrombosis and Disseminated Intravascular Coagulation

#### Short Name: Thrombosis and DIC

#### Key Event Component

| Process           | Object   | Action    |
|-------------------|----------|-----------|
| Venous thrombosis | platelet | increased |

#### AOPs Including This Key Event

| AOP ID and Name                                                                                                                                                                                       | Event Type     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| <a href="#">Aop:379 - Increased susceptibility to viral entry and coronavirus production leading to thrombosis and disseminated intravascular coagulation</a>                                         | AdverseOutcome |
| <a href="#">Aop:395 - Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on pericytes leads to disseminated intravascular coagulation resulting in cerebrovascular disease (stroke)</a> | KeyEvent       |

#### Stressors

##### Name

Sars-CoV-2

#### Biological Context

##### Level of Biological Organization

Organ

##### Organ term

##### Organ term

blood

#### Domain of Applicability

##### Taxonomic Applicability

| Term         | Scientific Term | Evidence | Links                |
|--------------|-----------------|----------|----------------------|
| Homo sapiens | Homo sapiens    | Moderate | <a href="#">NCBI</a> |

##### Life Stage Applicability

| Life Stage      | Evidence      |
|-----------------|---------------|
| All life stages | Not Specified |

##### Sex Applicability

| Sex        | Evidence      |
|------------|---------------|
| Unspecific | Not Specified |

Homo sapiens

**Key Event Description**

Thrombosis is defined as the formation or presence of a thrombus. Clotting within a blood vessel may cause infarction of tissues supplied by the vessel. Extreme aggravation of blood coagulation induces multiple thrombi in the microvasculature, which leads to consumption coagulopathy followed by disseminated intravascular coagulation (DIC).

DIC is a pathological syndrome resulting from the formation of thrombin, subsequent activation and consumption of coagulation proteins, and the production of fibrin thrombi. The initial pathologic events are thrombotic in nature resulting in thrombotic vascular occlusions. The initial clinical events are usually hemorrhagic resulting in oozing from mucosa and massive gastrointestinal blood loss. The occlusive events occur as a result of fibrin microthrombi or platelet microthrombi that obstruct the microcirculation of organs. This obstruction can result in organ hypoperfusion and ischemia, infarction, and necrosis. All organs are potentially vulnerable to the effects of thrombotic occlusions.

The renal effects of DIC are multifactorial and may be associated with hypovolemia or hypotension. If the hypotension is not corrected it may lead to renal failure due to acute tubular necrosis. Fibrin thrombi may also block glomerular capillaries causing ischemic, renal cortical necrosis (Colman, 1984).

The cerebral effects of DIC often result in nonspecific changes such as altered state of consciousness, convulsions, and coma. Major vascular occlusions, subarachnoid hemorrhage, multiple cortical and brain stem hemorrhages may occur following microvascular occlusions (Schwartzman RJ, 1982).

The pulmonary effects of DIC may be caused by interstitial hemorrhage resulting in a clinical effect resembling acute respiratory distress syndrome (Schwartzman RJ, 1973; Shahl RL, 1984).

**How it is Measured or Detected**

Clinical laboratory tests are used to diagnose DIC.

**Prothrombin time (PT)** is a blood test that measures how long it takes blood to clot. PT measures the time required for fibrin clot formation after the addition of tissue thromboplastin and calcium. The average time range for blood to clot is about 10 to 13 seconds.

**Activated partial prothrombin time (APTT).** Platelet poor plasma [PPP] is incubated at 37°C then phospholipid (cephalin) and a contact activator (e.g. Kaolin, micronized silica, or ellagic acid) are added. This leads to the conversion of Factor XI [FXI] to FXIa. The remainder of the pathway is not activated as no calcium is present. The addition of calcium (pre-warmed to 37°C) initiates clotting. The APTT is the time taken from the addition of calcium to the formation of a fibrin clot. The clotting time for the APTT lies between 27-35 seconds.

**Decreased fibrinogen concentrations**

Diluted plasma is clotted with a high concentration of Thrombin. The tested plasma is diluted (usually 1:10 but this may vary if the Fibrinogen concentration is very low or very high) to minimize the effect of 'inhibitory substances' within the plasma e.g. heparin, elevated levels of FDPs. The use of a high concentration of Thrombin (typically 100 U/ml) ensures that the clotting times are independent of Thrombin concentration over a wide range of Fibrinogen levels.

The test requires a reference plasma with a known Fibrinogen concentration and that has been calibrated against a known international reference standard. A calibration curve is constructed using this reference plasma by preparing a series of dilutions (1:5 –1:40) in the buffer to give a range of Fibrinogen concentrations. The clotting time of each of these dilutions is established (using duplicate samples) and the results (clotting time(s)/Fibrinogen concentration (g/L) are plotted on Log-Log graph paper. The 1:10 concentration is considered to be 100% i.e. normal. There should be a linear correlation between clotting times in the region of 10-50 sec.

The test platelet-poor diluted plasma (diluted 1:10 in buffer) is incubated at 37°C, Thrombin [~100 U/mL] added (all pre-warmed to 37°C). The time taken for the clot to form is compared to the calibration curve and the Fibrinogen concentration deduced. Test samples whose clotting times fall out with the linear part of the calibration curve should be re-tested using different dilutions.

Most laboratories use an automated method in which clot formation is deemed to have occurred when the optical density of the mixture has exceeded a certain threshold.

### Platelet Measurements-

A platelet count is the number of platelets a person has per microliter. The ideal platelet range is 150,000 – 400,000 per microliter in most healthy people.

### Fibrinolysis measurements-

d-dimer concentration ALERE TRIAGE® D-DIMER TEST

D-Dimer can be measured by a fluorescence immunoassay. To determine cross-linked fibrin degradation products containing D-dimer in EDTA anticoagulated whole blood and plasma specimens. The test is used as an aid in the assessment and evaluation of patients suspected of having disseminated intravascular coagulation or thromboembolic events including pulmonary embolism

### Procedure:

Commercially available kits are available to measure d-dimer in whole blood or plasma. The kits contain all the reagents necessary for the quantification of cross-linked fibrin degradation products containing D-dimer in EDTA anticoagulated whole blood or plasma specimens.

## Regulatory Significance of the AO

Thrombosis is one of the world's main concerns in terms of severe symptoms or adverse responses of the vaccine for COVID-19 which is caused by SARS-CoV-2. Excess thrombosis leads to DIC, which might be mortal. For safely developing the therapeutics and vaccines of COVID-19, it is regulatory significant to understand the cellular and molecular mechanisms in the pathogenesis of coronaviral infection, which may include thrombosis and DIC, AO1846.

## References

Hemostasis and Thrombosis Basic Principles and Clinical Practices Robert W Colman, Jack Hirsh, Victor J. Marder, Edwin W. Salzman (ed) Philadelphia, 1994.

Schwartzman RJ, Hill JB: Neurologic complications of DIC. Neurology 32:791, 1982

Robboy SJ, Minna JD, Colman RW et.al. Pulmonary hemorrhage syndrome as a manifestation of DIC: Analysis of 10 cases. Chest 63:718, 1973.

Stahl RL, Javid JP, Lackner H: Unrecognized pulmonary embolism presenting as DIC. SM J Med 76:772, 1984.

## Appendix 2

### List of Key Event Relationships in the AOP

#### List of Adjacent Key Event Relationships

#### [Relationship: 2310: Increased susceptibility to viral entry leads to Increased SARS-CoV-2 production](#)

#### AOPs Referencing Relationship

| AOP Name                                                                                                                                            | Adjacency | Weight of Evidence | Quantitative Understanding |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------|----------------------------|
| <a href="#">Increased susceptibility to viral entry and coronavirus production leading to thrombosis and disseminated intravascular coagulation</a> | adjacent  | High               | Moderate                   |
| <a href="#">Binding of viral S-glycoprotein to ACE2 receptor leading to acute respiratory distress associated mortality</a>                         | adjacent  | High               | High                       |
| <a href="#">SARS-CoV-2 infection leading to hyperinflammation</a>                                                                                   | adjacent  |                    |                            |
| <a href="#">Binding of SARS-CoV-2 to ACE2 in enterocytes leads to increased intestinal permeability resulting in GI disorders</a>                   | adjacent  |                    |                            |

#### [Relationship: 2358: Increased SARS-CoV-2 production leads to Response to ROS](#)

#### AOPs Referencing Relationship

| AOP Name                                                                                                                                            | Adjacency | Weight of Evidence | Quantitative Understanding |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------|----------------------------|
| <a href="#">Increased susceptibility to viral entry and coronavirus production leading to thrombosis and disseminated intravascular coagulation</a> | adjacent  | Moderate           | Not Specified              |
| <a href="#">SARS-CoV-2 infection leading to hyperinflammation</a>                                                                                   | adjacent  |                    |                            |

### Relationship: 2359: Response to ROS leads to Coagulation

#### AOPs Referencing Relationship

| AOP Name                                                                                                                                            | Adjacency | Weight of Evidence | Quantitative Understanding |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------|----------------------------|
| <a href="#">Increased susceptibility to viral entry and coronavirus production leading to thrombosis and disseminated intravascular coagulation</a> | adjacent  | Moderate           | Not Specified              |

### Relationship: 2360: Coagulation leads to Response to ROS

#### AOPs Referencing Relationship

| AOP Name                                                                                                                                            | Adjacency | Weight of Evidence | Quantitative Understanding |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------|----------------------------|
| <a href="#">Increased susceptibility to viral entry and coronavirus production leading to thrombosis and disseminated intravascular coagulation</a> | adjacent  | Moderate           | Not Specified              |

### Relationship: 2290: Coagulation leads to Thrombosis and DIC

#### AOPs Referencing Relationship

| AOP Name                                                                                                                                            | Adjacency | Weight of Evidence | Quantitative Understanding |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------|----------------------------|
| <a href="#">Increased susceptibility to viral entry and coronavirus production leading to thrombosis and disseminated intravascular coagulation</a> | adjacent  | High               |                            |

#### Evidence Supporting Applicability of this Relationship

##### Taxonomic Applicability

| Term         | Scientific Term | Evidence | Links                |
|--------------|-----------------|----------|----------------------|
| Homo sapiens | Homo sapiens    | High     | <a href="#">NCBI</a> |

##### Life Stage Applicability

| Life Stage      | Evidence |
|-----------------|----------|
| All life stages | High     |

##### Sex Applicability

| Sex        | Evidence |
|------------|----------|
| Unspecific | High     |

#### Key Event Relationship Description

Many regulators are involved in coagulation system. Plasmin is one of the modulators required for dissolution of the fibrin clot. Plasmin is activated by tissue plasminogen activator (tPA) and urokinase plasminogen activation (uPA). SERPINS inhibit thrombin, plasmin and tPA. For example, SERPINE1 or plasminogen activator inhibitor-1 (PAI-1) inhibits tPA/uPA and results in hypofibrinolysis [Bernard I, et al. Viruses. 2021; 13(1):29.]. In addition, SERPING1 inhibits FXII, and thus down-regulation of SERPING1 lifts suppression of FXII of the intrinsic coagulation cascade [Garvin et al. eLife 2020;9:e59177]. Protein C, protein S and thrombomodulin degrade FVa and FVIIIa. [Ref. IPA, Coagulation System, version 60467501, release date: 2020-11-19]

## Quantitative Understanding of the Linkage

### Known Feedforward/Feedback loops influencing this KER

Decreased fibrinolysis is involved in coagulation system. Coagulopathy may also be involved in this KER. [Mast AE et al, Garvin MR et al.]

### References

1. Bernard I, Limonta D, Mahal LK, Hobman TC. Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19. *Viruses*. 2021; 13(1):29. DOI: <https://doi.org/10.3390/v13010029>
2. Garvin et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. *eLife* 2020;9:e59177. DOI: <https://doi.org/10.7554/eLife.59177>
3. Mast AE, Wolberg AS, Gailani D, Garvin MR, Alvarez C, Miller JI, Aronow B, Jacobson D (2021) SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung. *eLife* 10:e64330. doi:10.7554/eLife.64330
4. Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, Mast AE, Justice A, Aronow B, Jacobson D (2020) A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. *eLife* 9:e59177. doi:10.7554/eLife.59177